US20090118128A1 - Preparation of templates for nucleic acid sequencing - Google Patents
Preparation of templates for nucleic acid sequencing Download PDFInfo
- Publication number
- US20090118128A1 US20090118128A1 US11/989,169 US98916906A US2009118128A1 US 20090118128 A1 US20090118128 A1 US 20090118128A1 US 98916906 A US98916906 A US 98916906A US 2009118128 A1 US2009118128 A1 US 2009118128A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- double
- strand
- stranded nucleic
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CCCCCNCC(C=C)=O Chemical compound *CCCCCNCC(C=C)=O 0.000 description 1
- UUILKUHGCPEEQQ-UHFFFAOYSA-N C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CC(=O)OCCCCBr.CC(=O)OCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.[Br-] Chemical compound C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CC(=O)OCCCCBr.CC(=O)OCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.[Br-] UUILKUHGCPEEQQ-UHFFFAOYSA-N 0.000 description 1
- KVLNTIPUCYZQHA-UHFFFAOYSA-N C=CC(=O)NCCCCCNC(=O)CBr Chemical compound C=CC(=O)NCCCCCNC(=O)CBr KVLNTIPUCYZQHA-UHFFFAOYSA-N 0.000 description 1
- QVCURWGCRCHODB-UHFFFAOYSA-N C=CC(=O)NCCCCCNC(=O)OC(C)(C)C Chemical compound C=CC(=O)NCCCCCNC(=O)OC(C)(C)C QVCURWGCRCHODB-UHFFFAOYSA-N 0.000 description 1
- ZCRMDPWPESABOU-UHFFFAOYSA-O C=CC(=O)NCCCCC[NH3+].O=C([O-])C(F)(F)F Chemical compound C=CC(=O)NCCCCC[NH3+].O=C([O-])C(F)(F)F ZCRMDPWPESABOU-UHFFFAOYSA-O 0.000 description 1
- XLZVQHWSQSPZBH-UHFFFAOYSA-L CC(=O)OC(CCCOP(C)(=O)[O-])C(CCCOP(C)(=O)[O-])OC(C)=O Chemical compound CC(=O)OC(CCCOP(C)(=O)[O-])C(CCCOP(C)(=O)[O-])OC(C)=O XLZVQHWSQSPZBH-UHFFFAOYSA-L 0.000 description 1
- XZACVZIGXAFYFK-RQCPZROWSA-N CC(=O)OCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.COC1=CC=C(C(OCCCCC/C=C/CCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.[Br-].[H]C(=O)CCCCCOC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 Chemical compound CC(=O)OCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.COC1=CC=C(C(OCCCCC/C=C/CCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.[Br-].[H]C(=O)CCCCCOC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 XZACVZIGXAFYFK-RQCPZROWSA-N 0.000 description 1
- PPIOYNONMWWRCH-CTHWIYDJSA-N CC(C)(C)[Si]([Cl-])(C1=CC=CC=C1)C1=CC=CC=C1.COC1=CC=C(C(OCCCCC/C=C/CCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.COC1=CC=C(C(OCCCCC/C=C/CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 Chemical compound CC(C)(C)[Si]([Cl-])(C1=CC=CC=C1)C1=CC=CC=C1.COC1=CC=C(C(OCCCCC/C=C/CCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.COC1=CC=C(C(OCCCCC/C=C/CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 PPIOYNONMWWRCH-CTHWIYDJSA-N 0.000 description 1
- OOHQDKCLVBFDRZ-UHFFFAOYSA-N CCCCC(=O)NCC1=CC(C(C)OP(C)OC=NCC)=C([N+](=O)[O-])C=C1 Chemical compound CCCCC(=O)NCC1=CC(C(C)OP(C)OC=NCC)=C([N+](=O)[O-])C=C1 OOHQDKCLVBFDRZ-UHFFFAOYSA-N 0.000 description 1
- WBKFXMFAJJVDFM-UHFFFAOYSA-N CN1(O)CCOCC1.COC1=CC=C(C(OCCCCCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.[H]C(=O)CCCCCOC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 Chemical compound CN1(O)CCOCC1.COC1=CC=C(C(OCCCCCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.[H]C(=O)CCCCCOC(C1=CC=CC=C1)(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 WBKFXMFAJJVDFM-UHFFFAOYSA-N 0.000 description 1
- GFVINZOAJURWKU-FXDYKFNQSA-N COC1=CC=C(C(OCCCCC/C=C/CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.COC1=CC=C(C(OCCCCCC(O)C(O)CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 Chemical compound COC1=CC=C(C(OCCCCC/C=C/CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.COC1=CC=C(C(OCCCCCC(O)C(O)CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 GFVINZOAJURWKU-FXDYKFNQSA-N 0.000 description 1
- WTALVXHVZJHXLX-UHFFFAOYSA-N COC1=CC=C(C(OCCCCCC(O)C(O)CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.COC1=CC=C(C(OCCCCCC(OC(C)=O)C(CCCO)OC(C)=O)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 Chemical compound COC1=CC=C(C(OCCCCCC(O)C(O)CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.COC1=CC=C(C(OCCCCCC(OC(C)=O)C(CCCO)OC(C)=O)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 WTALVXHVZJHXLX-UHFFFAOYSA-N 0.000 description 1
- SPBYDBDMHRUSHR-UHFFFAOYSA-N COC1=CC=C(C(OCCCCCC(OC(C)=O)C(CCCOP(OCCC#N)N(C(C)C)C(C)C)OC(C)=O)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 Chemical compound COC1=CC=C(C(OCCCCCC(OC(C)=O)C(CCCOP(OCCC#N)N(C(C)C)C(C)C)OC(C)=O)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1 SPBYDBDMHRUSHR-UHFFFAOYSA-N 0.000 description 1
- BWJAASNYSPIOJM-UHFFFAOYSA-N COC1=CC=C(C(OCCCCCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.OCCCCCCO Chemical compound COC1=CC=C(C(OCCCCCCO)(C2=CC=CC=C2)C2=CC=C(OC)C=C2)C=C1.OCCCCCCO BWJAASNYSPIOJM-UHFFFAOYSA-N 0.000 description 1
- BWJCPPMNKYJNQX-FAULWMFISA-L CP(C)(=O)OCCOCCNC(=O)C(=O)NCCCOCCOCCOCCCNC(=O)C(=O)N[C@H]1CC[C@@H](OP(C)(=O)[O-])CC1.CP(C)(=O)OCCOCCNC(=O)[C@H](O)[C@H](O)C(=O)NCCOC(=O)C(=O)NC1CCC(OP(C)(=O)[O-])CC1 Chemical compound CP(C)(=O)OCCOCCNC(=O)C(=O)NCCCOCCOCCOCCCNC(=O)C(=O)N[C@H]1CC[C@@H](OP(C)(=O)[O-])CC1.CP(C)(=O)OCCOCCNC(=O)[C@H](O)[C@H](O)C(=O)NCCOC(=O)C(=O)NC1CCC(OP(C)(=O)[O-])CC1 BWJCPPMNKYJNQX-FAULWMFISA-L 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00608—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00675—In-situ synthesis on the substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
Definitions
- the invention relates to the preparation of templates for nucleic acid sequencing reactions and to methods of sequencing such templates.
- the invention relates to the preparation of template nucleic acid molecules ready for sequencing by cleavage of one or both strands of a double-stranded nucleic acid immobilised on a solid support.
- Nucleic acid sequencing methods have been known in the art for many years.
- One of the best-known methods is the Sanger “dideoxy” method which relies upon the use of dideoxyribonucleoside triphosphates as chain terminators.
- the Sanger method has been adapted for use in automated sequencing with the use of chain terminators incorporating fluorescent labels.
- nucleic acid sequencing is based on successive cycles of incorporation of fluorescently labelled nucleic acid analogues.
- sequencing by synthesis or “cycle sequencing” methods the identity of the added base is determined after each nucleotide addition by detecting the fluorescent label.
- U.S. Pat. No. 5,302,509 describes a method for sequencing a polynucleotide template which involves performing multiple extension reactions using a DNA polymerase or DNA ligase to successively incorporate labelled polynucleotides complementary to a template strand.
- a “sequencing by synthesis” reaction a new polynucleotide strand based-paired to the template strand is built up in the 5′ to 3′ direction by successive incorporation of individual nucleotides complementary to the template strand.
- the substrate nucleoside triphosphates used in the sequencing reaction are labelled at the 3′ position with different 3′ labels, permitting determination of the identity of the incorporated nucleotide as successive nucleotides are added.
- nucleic acid array technology typically consist of a high-density matrix of polynucleotides immobilised onto a solid support material.
- WO 98/44151 and WO 00/18957 both describe methods of nucleic acid amplification which allow amplification products to be immobilised on a solid support in order to form arrays comprised of clusters or “colonies” formed from a plurality of identical immobilised polynucleotide strands and a plurality of identical immobilised complementary strands.
- Arrays of this type are referred to herein as “clustered arrays”.
- the nucleic acid molecules present in DNA colonies on the clustered arrays prepared according to these methods can provide templates for sequencing reactions, for example as described in WO 98/44152.
- bridged structures formed by annealing of pairs of immobilised polynucleotide strands and immobilised complementary strands, both strands being attached to the solid support at the 5′ end.
- Arrays comprised of such bridged structures provide inefficient templates for nucleic acid sequencing, since hybridisation of a conventional sequencing primer to one of the immobilised strands is not favoured compared to annealing of this strand to its immobilised complementary strand under standard hybridisation conditions.
- bridged template structures may be linearised by cleavage of one or both strands with a restriction endonuclease.
- restriction enzymes for linearisation is that it requires the presence of a specific recognition sequence for the enzyme at a suitable location in the bridged template structure. There is a risk that the same recognition sequence may appear elsewhere in the bridged structure, meaning that the enzyme may cut at one or more further sites, in addition to the intended cleavage site for linearisation. This may be a particular problem where the bridged structures to be linearised are derived by solid-phase amplification of templates of partially unknown sequence, since it cannot be predicted in advance whether a particular enzyme will cut within the region of unknown sequence.
- the invention provides methods of template linearisation which do not require cleavage with restriction endonucleases, or with nicking endonucleases.
- the invention in another general aspect relates to methods of template linearisation which are compatible with a particular type of solid supported microarray. More specifically, the invention provides linearisation methods which are compatible with arrays formed on solid supported polyacrylamide hydrogels.
- hydrogel-based solid-supported molecular arrays In preparing hydrogel-based solid-supported molecular arrays, a hydrogel is formed and molecules displayed from it. These two features—formation of the hydrogel and construction of the array—may be effected sequentially or simultaneously. Where the hydrogel is formed prior to formation of the array, it is typically produced by allowing a mixture of co-monomers to polymerise. Generally, the mixture of co-monomers contain acrylamide and one or more co-monomers, the latter of which permit, in part, subsequent immobilisation of molecules of interest so as to form the molecular array.
- the co-monomers used to create the hydrogel typically contain a functionality that serves to participate in crosslinking of the hydrogel and/or immobilise the hydrogel to the solid support and facilitate association with the target molecules of interest.
- clustered arrays may be formed on such solid-supported hydrogels by solid phase nucleic acid amplification using forward and reverse amplification primers attached to the hydrogel at their 5′ ends, leading to the production of clustered arrays of amplification products having a “bridged” structure.
- forward and reverse amplification primers attached to the hydrogel at their 5′ ends
- the invention provides a method of generating a template for a nucleic acid sequencing reaction comprising,
- step (ii) does not comprise cleavage with a restriction endonuclease or a nicking endonuclease.
- the invention provides method of generating a template for a nucleic acid sequencing reaction comprising,
- step (i) providing at least one double-stranded nucleic acid molecule, wherein both strands of the double-stranded nucleic acid molecule are attached to a solid support at the 5′ end, (ii) cleaving one or both strands of the double-stranded nucleic acid molecule, and (iii) subjecting the cleaved strand(s) to denaturing conditions to remove the portion of the cleaved strand(s) not attached to the solid support, thereby generating a partially or substantially single-stranded template for a nucleic acid sequencing reaction, characterised in that step (ii) does not comprise cleavage with a restriction endonuclease or a nicking endonuclease.
- the double-stranded stranded nucleic acid molecule may be cleaved at a pre-determined cleavage site.
- pre-determined cleavage site is meant a site whose location is determined in advance of the cleavage reaction, as opposed to cleavage at a random site the location of which is not known in advance.
- cleavage may occur at a cleavage site in one or both strands of the double-stranded nucleic acid molecule which comprises one or more or any combination of non-natural nucleotides, ribonucleotides or a non-nucleotide chemical modifications.
- the position of this cleavage site is preferably pre-determined.
- the double-stranded nucleic acid molecule may be cleaved in one or both strands via a non-enzymatic chemical cleavage reaction.
- one strand of the double-stranded nucleic acid molecule may comprise a diol linker and this strand may be cleaved by treatment with periodate.
- one strand of the double-stranded nucleic acid molecule may be treated to generate an abasic site and then cleaved at the abasic site.
- the abasic site may be generated by treatment with uracil DNA glycosylase and then cleaved with endonuclease, heat treatment or alkali treatment.
- one strand of the double-stranded nucleic acid may comprise one or more ribonucleotides and step (ii) may comprise cleaving this strand adjacent to a ribonucleotide using an RNAse or a non-enzymatic chemical cleavage agent.
- Suitable non-enzymatic chemical cleavage agents include metal ions, and in particular rare earth metal ions, e.g. La 3+ or Lu 3+ .
- one strand of the double-stranded nucleic acid may comprise one or more methylated nucleotides and step (ii) may comprise cleaving this strand using an enzyme specific for a recognition sequence including said methylated nucleotide(s).
- step (ii) may comprise cleaving one or both strands of the double-stranded nucleic acid in a photochemical reaction.
- one strand of the double-stranded nucleic acid molecule may have a peptide covalently linked at the 5′ end and step (ii) may comprise cleaving the peptide.
- the invention also provides methods of sequencing nucleic acid templates generated according to the methods of the first and second aspects of the invention.
- FIG. 1 is a schematic illustration of cluster formation by solid-phase PCR and subsequent linearisation and annealing of a sequencing primer.
- the starting material in step (a) is a solid support grafted with a mixture of amplification primers, one of which comprises a cleavage site.
- the primers are covalently attached to the solid support at the 5′ end.
- a substrate molecule to be amplified is also applied to the solid support, either by hybridisation to one of the immobilised primers or by direct covalent attachment to the support at the 5′ end.
- FIG. 1( b ) schematically illustrates the “bridged” amplification products resulting from solid phase amplification. For simplicity only a small number of bridged products are shown.
- the amplification products are then “linearised” by cleavage at the cleavage sites derived from the amplification primers ( FIG. 1( c )).
- the products of the cleavage reaction may then be subjected to denaturing conditions, resulting in removal of the portions of the cleaved strands which are no longer covalently attached to the solid support ( FIG. 1( d )).
- the remaining single stranded products may then be hybridised to a sequencing primer ( FIG. 1( e )).
- FIG. 2 is a schematic illustration of linearisation by cleavage at an abasic site generated by treatment of a U-containing polynucleotide with uracil DNA glycosylase.
- Bridged amplification products are generated by amplification of the template structure schematically illustrated in FIG. 2( a ) with primers immobilised on a solid support.
- One of the amplification primers contains a deoxyuridine nucleotide represented as U.
- a single bridged product is illustrated in FIG. 2( b ) for simplicity.
- An abasic site is generated in one strand by treatment with uracil DNA glycosylase.
- This strand may then be cleaved by hydrolysis of the abasic site to generate the “nicked” structure illustrated in FIG. 2( c ). Hydrolysis of the abasic site generates a free 3′ hydroxyl group which can serve as an initiation point for a sequencing reaction. Sequencing may be carried out using a strand displacing polymerase (as shown in FIG. 2( d ), or the portion of the cleaved strand not attached to the solid support may be removed by denaturation prior to sequencing. In the latter case the sequencing reaction could be initiated by hybridisation of a sequencing primer as an alternative to priming from the cleaved strand itself.
- FIG. 3 illustrates linearisation by cleavage with a restriction enzyme.
- FIG. 3( a ) shows the sequence of a representative double-stranded nucleic acid molecule which includes sequences derived from the amplification primers P5 and P7 utilised in the accompanying examples, a restriction site for cleavage by the enzyme BglII and a site for binding of a sequencing primer.
- “Genomic” represents a sequence derived from a genomic DNA fragment. The genomic fragment will typically be from 400-700b in length, although the invention is not limited to sequences of this length, and may be of known, partially known or unknown sequence.
- FIG. 3 illustrates linearisation by cleavage with a restriction enzyme.
- FIG. 3( a ) shows the sequence of a representative double-stranded nucleic acid molecule which includes sequences derived from the amplification primers P5 and P7 utilised in the accompanying examples, a restriction site for cleavage by the enzyme BglII and
- FIG. 3( b ) schematically illustrates linearisation of a single bridged double-stranded nucleic acid product having the sequence shown in FIG. 3( a ).
- the two complementary strands forming the bridged product are covalently attached to a solid support at their 5′ ends.
- the bridged product is first cleaved with BglII and then denatured to remove substantially all of one strand.
- the single strand remaining on the solid support may then be hybridised to a sequencing primer.
- FIG. 4 graphically illustrates cleavage of a diol linker by treatment with sodium periodate.
- FIG. 5 shows signal intensity versus time for SyBr green stained colonies treated with periodate, illustrating selective cleavage of colonies containing diol linkers.
- FIG. 6 graphically illustrates cleavage of colonies containing diol linkers.
- FIG. 7 is a schematic representation of an 8 channel flowcell suitable for carrying out the methods of the invention.
- FIG. 8 illustrates the structure and sequence of an exemplary DNA template used for solid-phase PCR amplification in the accompanying examples. Sequences of the amplification primers P5 and P7 are shown in bold type.
- FIG. 9 shows fluorescent CCD images of clustered arrays of nucleic acid colonies following a single cycle of nucleotide incorporation under standard sequencing conditions.
- Panel (A) illustrates nucleotide incorporation on colonies of nucleic acids which have not been linearised.
- Panel (B) illustrates nucleotide incorporation of colonies of nucleic acid templates which have been linearised by periodate cleavage of a diol linker.
- FIG. 10 shows histogram plots (fluorescence intensity vs number of colonies) corresponding to the fluorescent CCD images shown in FIG. 9 .
- the invention generally relates to methods of forming templates for nucleic acid sequencing starting from double-stranded nucleic acid molecules immobilised on a solid support, and to methods of sequencing such templates.
- the double-stranded nucleic acid molecules which provide the starting point for sequencing template formation according to the first and second aspects of the invention are characterised in that they are formed from annealed complementary nucleic acid strands that are attached to the solid support at their 5′ ends, preferably via covalent attachment.
- the complementary strands of the double-stranded nucleic acid molecule are annealed, such as will generally be the case when the molecules are maintained under non-denaturing conditions, such molecules may be referred to herein as “bridged” structures.
- the methods of template formation provided by the invention involve cleavage of one or both strands of the double-stranded molecule. Following the cleavage step the cleaved products may be subjected to denaturing conditions so as to remove the portion(s) of the cleaved strand(s) which are not attached to the solid support, i.e. the portion located downstream of the site of cleavage when a given strand is viewed 5′ to 3′.
- the resulting template molecule will be at least partially single-stranded and may be substantially single-stranded.
- the length of the single-stranded portion will depend on the position of the cleavage site relative to the 5′ ends of the complementary strands and whether the cleavage step cuts one or both strands. It will be appreciated that the location of the cleavage site determines how much of each strand remains attached to the solid support after cleavage and denaturation.
- the double-stranded nucleic acid molecule from which the sequencing template is to be derived comprises two annealed (complementary) polynucleotide strands which are both attached to a solid support at or near the 5′ end. Linkage to the solid support will preferably be via covalent attachment. It will be appreciated that the annealed strands need not necessarily be fully complementary along their entire length.
- the terms “immobilised” and “attached” are used interchangeably herein and both terms are intended to encompass direct or indirect, covalent or non-covalent attachment, unless indicated otherwise, either explicitly or by context.
- covalent attachment may be preferred, but generally all that is required is that the molecules (e.g. nucleic acids) remain immobilised or attached to the support under the conditions in which it is intended to use the support, for example in applications requiring nucleic acid amplification and/or sequencing.
- Certain embodiments of the invention make use of solid supports comprised of an inert substrate or matrix (e.g. glass slides, polymer beads etc) which is been “functionalised”, for example by application of a layer or coating of an intermediate material comprising reactive groups which permit covalent attachment to biomolecules, such as polynucleotides.
- an intermediate material comprising reactive groups which permit covalent attachment to biomolecules, such as polynucleotides.
- examples of such supports include, but are not limited to, polyacrylamide hydrogels supported on an inert substrate such as glass.
- the biomolecules e.g. polynucleotides
- the intermediate material e.g. the hydrogel
- the intermediate material may itself be non-covalently attached to the substrate or matrix (e.g. the glass substrate).
- covalent attachment to a solid support is to be interpreted accordingly as encompassing this type of arrangement.
- covalent attachment can be achieved through a sulphur-containing nucleophile, such as phosphorothioate, present at the 5′ end of a polynucleotide strand.
- a sulphur-containing nucleophile such as phosphorothioate
- this nucleophile will bind to a “C” group present in the hydrogel.
- the “double-stranded” nucleic acid to be cleaved may in fact be partially single-stranded at the 5′ end(s) of one or both strands.
- the double-stranded nucleic acid will typically be formed from two complementary polynucleotide strands comprised of deoxyribonucleotides joined by phosphodiester bonds, but may additionally include one or more ribonucleotides and/or non-nucleotide chemical moieties and/or non-naturally occurring nucleotides and/or non-naturally occurring backbone linkages.
- the double-stranded nucleic acid may include non-nucleotide chemical moieties, e.g. linkers or spacers, at the 5′ end of one or both strands.
- the double-stranded nucleic acid may include methylated nucleotides, uracil bases, phosphorothioate groups, also peptide conjugates etc.
- Such non-DNA or non-natural modifications may be included in order to permit cleavage, or to confer some other desirable property, for example to enable covalent attachment to a solid support, or to act as spacers to position the site of cleavage an optimal distance from the solid support.
- the site for cleavage of a strand of the double-stranded nucleic acid may, depending on the nature of the cleavage reaction, be positioned in a region of the molecule that is single-stranded when the complementary strands are annealed.
- the double-stranded nucleic acid may in fact be partially single-stranded at one or both 5′ ends, e.g. proximal to the site of linkage to the solid support. It is within the scope of the invention for a cleavage site to be positioned within such a single-stranded region.
- the cleavage site may be present in a non-nucleotide chemical moiety covalently attached to the 5′ end of one strand of the double-stranded nucleic acid, for example a linker moiety.
- the double-stranded nucleic acid will typically comprise a “target” region that it is desired to fully or partially sequence.
- the nature of the target region is not limiting to the invention. It may be of previously known or unknown sequence and may be derived, for example, from a genomic DNA fragment, a cDNA, etc.
- the double-stranded nucleic acid molecule may also include non-target sequences, for example at the 5′ and 3′ ends of both strands, flanking the target region. If the double-stranded nucleic acid is formed by solid-phase nucleic acid amplification, these non-target sequences may be derived from the primers used for the amplification reaction. Sites for cleavage of one or both strands of the double-stranded nucleic acid may be positioned in the non-target sequences.
- the double-stranded nucleic acid may form part of a cluster or colony comprised of many such double-stranded nucleic acid molecules, and the cluster or colony may itself form part of an array of such clusters or colonies, referred to herein as a “clustered array”.
- a cluster or colony comprised of many such double-stranded nucleic acid molecules
- the cluster or colony may itself form part of an array of such clusters or colonies, referred to herein as a “clustered array”.
- each double-stranded nucleic acid molecule within each colony will comprise the same target region, whereas different colonies may be formed of double-stranded nucleic acid molecules comprising different target regions.
- At least 90%, more preferably at least 95% of the colonies on a given clustered array will be formed from double-stranded nucleic acid molecules comprising different target regions, although within each individual colony on the array all double-stranded nucleic acid molecules will comprise the same target region.
- all double-stranded nucleic acid molecules within all of the colonies on the array comprise the same type of cleavage site. This is preferred even when different colonies on the array are formed of double-stranded nucleic acid molecules comprising different target regions, since it enables all the double-stranded molecules on the array to be cleaved simultaneously under identical cleavage reaction conditions.
- cleavage methods may be used in accordance in accordance with the first and second aspects of the invention to cleave one or both strands of the double-stranded nucleic acid molecule. Preferred but non-limited embodiments of suitable cleavage methods are discussed in further detail below. Methods i) to vii) are common to the first and second aspects of the invention.
- chemical cleavage encompasses any method which utilises a non-nucleic acid and non-enzymatic chemical reagent in order to promote/achieve cleavage of one or both strands of the double-stranded nucleic acid molecule.
- one or both strands of the double-stranded nucleic acid molecule may include one or more non-nucleotide chemical moieties and/or non-natural nucleotides and/or non-natural backbone linkages in order to permit a chemical cleavage reaction at a pre-determined cleavage site.
- one strand of the double-stranded nucleic acid molecule may include a diol linkage which permits cleavage by treatment with periodate (e.g. sodium periodate).
- the diol linkage may be positioned at a pre-determined cleavage site, the precise location of which may be selected by the user. It will be appreciated that more than one diol could be included at the cleavage site.
- Diol linker units based on phosphoamidite chemistry suitable for incorporation into polynucleotide chains are commercially available from Fidelity systems Inc. (Gaithersburg, Md., USA). One or more diol units may be incorporated into a polynucleotide using standard methods for automated chemical DNA synthesis.
- one or more spacer molecules may be included between the diol linker and the site of attachment to the solid support.
- the spacer molecule may be a non-nucleotide chemical moiety. Suitable spacer units based on phosphoamidite chemistry for use in conjunction with diol linkers are also supplied by Fidelity Systems Inc.
- One suitable spacer for use with diol linkers is the spacer denoted arm 26 , identified in the accompanying examples. arm 26 may be modified to include a phosphorothioate group at the 5′ end in order to facilitate attachment of the 5′ end of the polynucleotide strand to a solid support. The phosphorothioate group can easily be attached during chemical synthesis of a “polynucleotide” chain including the spacer and diol units.
- spacer molecules could be used as an alternative to arm 26 .
- a stretch of non-target “spacer” nucleotides may be included. Typically from 1 to 20, more preferably from 1 to 15 or from 1 to 10, and more particularly 2, 3, 4, 5, 6, 7, 8, 9 or 10 spacer nucleotides may be included. Most preferably 10 spacer nucleotides will be positioned between the point of attachment of the polynucleotide strand to a solid support (typically the extreme 5′ end) and the diol linker. It is preferred to use polyT spacers, although other nucleotides and combinations thereof can be used. In one preferred embodiment the strand to be cleaved may include 10T spacer nucleotides upstream of the diol linker.
- the diol linker is cleaved by treatment with a “cleaving agent”, which can be any substance which promotes cleavage of the diol.
- the preferred cleaving agent is periodate, preferably aqueous sodium periodate (NaIO 4 ).
- the cleaved product may be treated with a “capping agent” in order to neutralise reactive species generated in the cleavage reaction.
- Suitable capping agents for this purpose include amines, such as ethanolamine.
- the capping agent e.g. ethanolamine
- the capping agent may be included in a mixture with the cleaving agent (e.g. periodate) so that reactive species are capped as soon as they are formed.
- a diol linkage and cleaving agent e.g. periodate
- cleaving agent e.g. periodate
- the invention is not intended to be limited to the use of diol linkages/periodate as a method of linearisation on polyacrylamide hydrogel surfaces but also extends to use of this cleavage method for linearisation of nucleic acids immobilised on other surfaces, including supports coated with functionalised silanes (etc).
- abasic site is defined as a nucleoside position in a polynucleotide chain from which the base component has been removed.
- Abasic sites can occur naturally in DNA under physiological conditions by hydrolysis of nucleoside residues, but may also be formed chemically under artificial conditions or by the action of enzymes. Once formed, abasic sites may be cleaved (e.g. by treatment with an endonuclease or other single-stranded cleaving enzyme, exposure to heat or alkali), providing a means for site-specific cleavage of a polynucleotide strand.
- an abasic site may be created at a pre-determined position on one strand of a double-stranded polynucleotide and then cleaved by first incorporating deoxyuridine (U) at a pre-determined cleavage site in the double-stranded nucleic acid molecule.
- U deoxyuridine
- UGG uracil DNA glycosylase
- the polynucleotide strand including the abasic site may then be cleaved at the abasic site by treatment with endonuclease (e.g. EndoIV endonuclease, AP lyase, FPG glycosylase/AP lyase, EndoVIII glycosylase/AP lyase), heat or alkali.
- endonuclease e.g. EndoIV endonuclease, AP lyase, FPG glycosylase/AP lyase, EndoVIII glycosylase/AP lyase
- Abasic sites may also be generated at non-natural/modified deoxyribonucleotides other than deoxyuridine and cleaved in an analogous manner by treatment with endonuclease, heat or alkali.
- endonuclease heat or alkali.
- 8-oxo-guanine can be converted to an abasic site by exposure to FPG glycosylase.
- Deoxyinosine can be converted to an abasic site by exposure to AlkA glycosylase.
- the abasic sites thus generated may then be cleaved, typically by treatment with a suitable endonuclease (e.g. EndoIV, AP lyase).
- the double-stranded nucleic acid molecule is formed by solid-phase PCR amplification using an amplification primer which comprises the relevant non-natural/modified nucleotide, then it is essential in this embodiment that the non-natural/modified nucleotide is capable of being copied by the polymerase used for the amplification reaction.
- the double-stranded nucleic acid molecules to be cleaved may be exposed to a mixture containing the appropriate glycosylase (to generate the abasic site) and one or more suitable endonucleases (to subsequently cleave).
- the glycosylase and the endonuclease will typically be present in an activity ratio of at least about 2:1.
- Cleavage of double stranded nucleic acids at pre-determined abasic sites has particular advantages in relation to the creation of templates for nucleic acid sequencing.
- cleavage at an abasic site generated by treatment with a glycosylase such as UDG generates a free 3′ hydroxyl group on the cleaved strand which can provide an initiation point for sequencing a region of the complementary strand.
- a glycosylase such as UDG
- deoxyuridine which does not occur naturally in DNA, but is otherwise independent of sequence context, if only one non-natural base is included there is no possibility of glycosylase-mediated cleavage occurring elsewhere at unwanted positions in the duplex.
- the enzyme may create nicks at other sites in the duplex (in addition to the desired cleavage site) if these possess the correct recognition sequence.
- Another advantage gained by cleavage of abasic sites in a double-stranded molecule generated by action of UDG on uracil is that the first base incorporated in a “sequencing-by-synthesis” reaction initiating at the free 3′ hydroxyl group formed by cleavage at such a site will always be T.
- the double-stranded nucleic acid molecule forms part of a clustered array comprised of many such molecules, all of which are cleaved in this manner to produce sequencing templates, then the first base universally incorporated across the whole array will be T. This can provide a sequence-independent assay for cluster intensity at the start of a sequencing “run”.
- incorporation of one or more ribonucleotides into a polynucleotide strand which is otherwise comprised of deoxyribonucleotides can provide a pre-determined site for cleavage using a chemical agent capable of selectively cleaving the phosphodiester bond between a deoxyribonucleotide and a ribonucleotide or using a ribonuclease (RNAse).
- RNAse ribonuclease
- the invention also encompasses production of sequencing templates by cleavage of one strand (of a double-stranded nucleic acid molecule) at a site containing one or more consecutive ribonucleotides using such a chemical cleavage agent or an RNase.
- the strand to be cleaved contains a single ribonucleotide to provide a pre-determined site for chemical cleavage.
- Suitable chemical cleavage agents capable of selectively cleaving the phosphodiester bond between a deoxyribonucleotide and a ribonucleotide include metal ions, for example rare-earth metal ions (especially La 3+ , particularly Tm 3+ , Yb 3+ or Lu 3+ (Chen et al. Biotechniques. 2002, 32: 518-520; Komiyama et al. Chem. Commun. 1999, 1443-1451)), Fe(3) or Cu(3), or exposure to elevated pH, e.g. treatment with a base such as sodium hydroxide.
- metal ions for example rare-earth metal ions (especially La 3+ , particularly Tm 3+ , Yb 3+ or Lu 3+ (Chen et al. Biotechniques. 2002, 32: 518-520; Komiyama et al. Chem. Commun. 1999, 1443-1451)), Fe(3) or Cu(3), or exposure to elevated pH, e.g
- selective cleavage of the phosphodiester bond between a deoxyribonucleotide and a ribonucleotide is meant that the chemical cleavage agent is not capable of cleaving the phosphodiester bond between two deoxyribonucleotides under the same conditions.
- the base composition of the ribonucleotide(s) is generally not material, but can be selected in order to optimise chemical (or enzymatic) cleavage.
- rUMP or rCMP are generally preferred if cleavage is to be carried out by exposure to metal ions, especially rare earth metal ions.
- the ribonucleotide(s) will typically be incorporated into one strand of the double-stranded nucleic acid molecule, and may be situated in a region thereof which is single-stranded when the two complementary strands of the double-stranded molecule are annealed (i.e. in a 5′ overhanging portion).
- the double-stranded nucleic acid molecule is prepared by solid-phase PCR amplification using forward and reverse amplification primers, one of which contains at least one ribonucleotide, the standard DNA polymerase enzymes used for PCR amplification are not capable of copying ribonucleotide templates.
- the products of the solid-phase PCR reaction will contain an overhanging 5′ region comprising the ribonucleotide(s) and any remainder of the amplification primer upstream of the ribonucleotide(s).
- the phosphodiester bond between a ribonucleotide and a deoxyribonucleotide, or between two ribonucleotides can also be cleaved by an RNase. Any endocytic ribonuclease of appropriate substrate specificity can be used for this purpose. If the ribonucleotide(s) are present in a region which is single-stranded when the two complementary strands of the double-stranded molecule are annealed (i.e. in a 5′ overhanging portion), then the RNase will be an endonuclease which has specificity for single strands containing ribonucleotides.
- ribonuclease For cleavage with ribonuclease it is preferred to include two or more consecutive ribonucleotides, and preferably from 2 to 10 or from 5 to 10 consecutive ribonucleotides.
- the precise sequence of the ribonucleotides is generally not material, except that certain RNases have specificity for cleavage after certain residues. Suitable RNases include, for example, RNaseA, which cleaves after C and U residues. Hence, when cleaving with RNaseA the cleavage site must include at least one ribonucleotide which is C or U.
- Polynucleotides incorporating one or more ribonucleotides can be readily synthesised using standard techniques for oligonucleotide chemical synthesis with appropriate ribonucleotide precursors. If the double-stranded nucleic acid molecule is prepared by solid-phase nucleic acid amplification, then it is convenient to incorporate one or more ribonucleotides into one of the primers to be used for the amplification reaction.
- photochemical cleavage encompasses any method which utilises light energy in order to achieve cleavage of one or both strands of the double-stranded nucleic acid molecule.
- a pre-determined site for photochemical cleavage can be provided by a non-nucleotide chemical spacer unit in one of the strands of the double-stranded molecule.
- Suitable photochemical cleavable spacers include the PC spacer phosphoamidite (4-(4,4′-Dimethoxytrityloxy)butyramidomethyl)-1-(2-nitrophenyl)-ethyl]-2-cyanoethyl-(N,N-diisopropyl)-phosphoramidite) supplied by Glen Research, Sterling, Va., USA (cat number 10-4913-XX) which has the structure:
- the spacer unit can be cleaved by exposure to a UV light source.
- This spacer unit can be attached to the 5′ end of a polynucleotide, together with a thiophosphate group which permits attachment to a solid surface, using standard techniques for chemical synthesis of oligonucleotides. Conveniently, this spacer unit can be incorporated into a forward or reverse amplification primer to be used for synthesis of a photocleavable double-stranded nucleic acid molecule by solid-phase amplification.
- Site-specific cleavage of one strand of a double-stranded nucleic acid molecule may also be achieved by incorporating one or more methylated nucleotides into this strand and then cleaving with an endonuclease enzyme specific for a recognition sequence including the methylated nucleotide(s).
- the methylated nucleotide(s) will typically be incorporated in a region of one strand of the double-stranded nucleic acid molecule having a complementary stretch of non-methylated deoxyribonucleotides on the complementary strand, such that annealing of the two strands produces a hemimethylated duplex structure.
- the hemimethylated duplex may then be cleaved by the action of a suitable endonuclease.
- enzymes which cleave such hemimethylated target sequences are not to be considered as “restriction endonucleases” excluded from the scope of the second aspect of the invention, but rather are intended to form part of the subject-matter of the invention.
- Polynucleotides incorporating one or methylated nucleotides may be prepared using standard techniques for automated DNA synthesis, using appropriately methylated nucleotide precursors. If the double-stranded nucleic acid molecule is prepared by solid-phase nucleic acid amplification, then it is convenient to incorporate one or more methylated nucleotides into one of the primers to be used for the amplification reaction.
- the double-stranded nucleic acid may be prepared by solid-phase amplification using forward and reverse primers, one of which contains a “PCR stopper”.
- a “PCR stopper” is any moiety (nucleotide or non-nucleotide) which prevents read-through of the polymerase used for amplification, such that it cannot copy beyond that point. The result is that amplified strands derived by extension of the primer containing the PCR stopper will contain a 5′ overhanging portion. This 5′ overhang (other than the PCR stopper itself) may be comprised of naturally occurring deoxyribonucleotides, with predominantly natural backbone linkages, i.e. it may simply be a stretch of single-stranded DNA.
- the molecule may then be cleaved in the 5′ overhanging region with the use of a cleavage reagent (e.g. an enzyme) which is selective for cleavage of single-stranded DNA but not double stranded DNA, for example mung bean nuclease.
- a cleavage reagent e.g. an enzyme which is selective for cleavage of single-stranded DNA but not double stranded DNA, for example mung bean nuclease.
- the PCR stopper may be essentially any moiety which prevents read-through of the polymerase to be used for the amplification reaction.
- Suitable PCR stoppers include, but are not limited to, hexaethylene glycol (HEG), abasic sites, and any non-natural or modified nucleotide which prevents read-through of the polymerase, including DNA analogues such as peptide nucleic acid (PNA).
- HOG hexaethylene glycol
- PNA peptide nucleic acid
- Stable abasic sites can be introduced during chemical oligonucleotide synthesis using appropriate spacer units containing the stable abasic site.
- abasic furan (5′-O-Dimethoxytrityl-1′,2′-Dideoxyribose-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite) spacers commercially available from Glen Research, Sterling, Va., USA, can be incorporated during chemical oligonucleotide synthesis in order to introduce an abasic site.
- Such a site can thus readily be introduced into an oligonucleotide primer to be used in solid-phase amplification.
- an abasic site is incorporated into either forward or reverse amplification primer the resulting amplification product will have a 5′ overhang on one strand which will include the abasic site (in single-stranded form).
- the single-stranded abasic site may then be cleaved by the action of a suitable chemical agent (e.g. exposure to alkali) or an enzyme (e.g. AP-endonuclease VI, Shida et al. Nucleic Acids Research, 1996, Vol. 24, 4572-4576).
- a cleavage site can also be introduced into one strand of the double-stranded nucleic molecule by preparing a conjugate structure in which a peptide molecule is linked to one strand of the nucleic acid molecule.
- the peptide molecule can subsequently be cleaved by a peptidase enzyme of the appropriate specificity, or any other suitable means of non-enzymatic chemical or photochemical cleavage.
- the conjugate between peptide and nucleic acid will be formed by covalently linking a peptide to one strand only of the double-stranded nucleic acid molecule, with the peptide portion being conjugated to the 5′ end of this strand, adjacent to the point of attachment to the solid surface.
- the peptide conjugate may be incorporated at the 5′ end of one of the amplification primers. Obviously the peptide component of this primer will not be copied during PCR amplification, hence the “bridged” amplification product will include a cleavable 5′ peptide “overhang” on one strand.
- Conjugates between peptides and nucleic acids wherein the peptide is conjugated to the 5′ end of the nucleic acid can be prepared using techniques generally known in the art.
- the peptide and nucleic acid components of the desired amino acid and nucleotide sequence can be synthesised separately, e.g. by standard automated chemical synthesis techniques, and then conjugated in aqueous/organic solution.
- the OPeCTM system commercially available from Glen Research is based on the “native ligation” of an N-terminal thioester-functionalized peptide to a 5′-cysteinyl oligonucleotide.
- Pentafluorophenyl S-benzylthiosuccinate is used in the final coupling step in standard Fmoc-based solid-phase peptide assembly. Deprotection with trifluoroacetic acid generates, in solution, peptides substituted with an N-terminal S-benzylthiosuccinyl group. O-trans-4-(N-a-Fmoc-S-tert-butylsulfenyl-1-cysteinyl)aminocyclohexyl 0-2-cyanoethyl-N,N-diisopropylphosphoramidite is used in the final coupling step in standard phosphoramidite solid-phase oligonucleotide assembly.
- the conjugate strand containing peptide and nucleic acid can be covalently attached to a solid support using any suitable covalent linkage technique known in the art which is compatible with the chosen surface.
- covalent attachment to a solid supported polyacrylamide hydrogel surface can be achieved by inclusion of a thiophosphate group on the “free” end of the peptide component (i.e. the end not conjugated to the nucleic acid).
- a thiophosphate group on the “free” end of the peptide component (i.e. the end not conjugated to the nucleic acid).
- the peptide component can be designed to be cleavable by any chosen peptidase enzyme, of which many are known in the art.
- the nature of the peptidase is not particularly limited, it is necessary only for the peptidase to cleave somewhere in the peptide component.
- the length and amino acid sequence of the peptide component is not particularly limited except by the need to be “cleavable” by the chosen peptidase.
- the length and precise sequence of the nucleic acid component is also not particularly limited, it may be of any desired sequence. If the nucleic acid component is to function as a primer in solid-phase PCR, then its length and nucleotide sequence will be selected to enable annealing to the template to be amplified.
- the product of the cleavage reaction may be subjected to denaturing conditions in order to remove the portion(s) of the cleaved strand(s) that are not attached to the solid support.
- denaturing conditions will be apparent to the skilled reader with reference to standard molecular biology protocols (Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, 3rd Ed, Cold Spring Harbor Laboratory Press, Cold Spring Harbor Laboratory Press, NY; Current Protocols, eds Ausubel et al.).
- Denaturation results in the production of a sequencing template which is partially or substantially single-stranded.
- a sequencing reaction may then be initiated by hybridisation of a sequencing primer to the single-stranded portion of the template.
- sequencing can be initiated directly after the cleavage step with no need for denaturation to remove a portion of the cleaved strand(s). If the cleavage step generates a free 3′ hydroxyl group on one cleaved strand still hybridised to a complementary strand then sequencing can proceed from this point using a strand-displacement polymerase enzyme without the need for an initial denaturation step.
- strand displacement sequencing may be used in conjunction with template generation by cleavage with nicking endonucleases, or by hydrolysis of an abasic site with endonuclease, heat or alkali treatment.
- solid support refers to the material to which the polynucleotides molecules are attached. Suitable solid supports are available commercially, and will be apparent to the skilled person.
- the supports can be manufactured from materials such as glass, ceramics, silica and silicon. Supports with a gold surface may also be used.
- the supports usually comprise a flat (planar) surface, or at least a structure in which the polynucleotides to be interrogated are in approximately the same plane.
- the solid support can be non-planar, e.g., a microbead. Any suitable size may be used.
- the supports might be on the order of 1-10 cm in each direction.
- the first aspect of the invention relates to generation of sequencing templates on a particular type of surface, namely solid supported polyacrylamide hydrogels.
- hydrogel-based solid-supported molecular arrays a hydrogel is formed and molecules displayed from it.
- the hydrogel is formed prior to formation of the array, it is typically produced by allowing a mixture of comonomers to polymerise.
- the mixture of comonomers contain acrylamide and one or more comonomers, the latter of which permit, in part, subsequent immobilisation of molecules of interest so as to form the molecular array.
- the comonomers used to create the hydrogel typically contain a functionality that serves to participate in crosslinking of the hydrogel and/or immobilise the hydrogel to the solid support and facilitate association with the target molecules of interest.
- polyacrylamide hydrogels are produced as thin sheets upon polymerisation of aqueous solutions of acrylamide solution.
- a multiply unsaturated (polyunsaturated) crosslinking agent such as bisacrylamide
- the ratio of acrylamide to bisacrylamide is generally about 19:1.
- Some form of covalent surface modification of the solid support may be practised in order to achieve satisfactory immobilisation of either hydrogel-based molecular arrays or hydrogels to which it is desired to array molecules.
- the inventors have observed that such functional modification of the support is not necessary in order to achieve satisfactory immobilisation of arrays of polynucleotides.
- a mixture of comonomers comprising at least one hydrophilic monomer and a functionalised comonomer (functionalised to the extent that the monomer once incorporated into the polymer is capable of binding the molecule of interest to the surface of the hydrogel) may be polymerised so as to form a hydrogel capable of being immobilised on a solid supported, preferably a silica-based, substrate.
- the hydrogel may be substantially free of any binder silane components.
- a first comonomer which is acrylamide, methacrylamide, hydroxyethyl methacrylate or N-vinyl pyrrolidinone;
- A is NR or O, wherein R is hydrogen or an optionally substituted saturated hydrocarbyl group comprising 1 to 5 carbon atoms;
- C is a group for reaction with a compound to bind said compound covalently to said hydrogel) to form a polymerised product
- Suitable supports include silica-based substrates, such as glass, fused silica and other silica-containing materials; they may also be silicone hydrides or plastic materials such as polyethylene, polystyrene, poly(vinyl chloride), polypropylene, nylons, polyesters, polycarbonates and poly(methyl methacrylate). Preferred plastics material are poly(methyl methacrylate), polystyrene and cyclic olefin polymer substrates. Alternatively, other solid supports may be used such as gold, titanium dioxide, or silicon supports. The foregoing lists are intended to be illustrative of, but not limited to, the invention.
- the support is a silica-based material or plastics material such as discussed herein.
- the methods by which the mixture of comonomers are polymerised in the invention are not characteristic of this invention and will be known to the skilled person (e.g. by recourse to Sambrook et al. (supra). Generally, however, the polymerisation will be conducted in an aqueous medium, and polymerisation initiated by any suitable initiator. Potassium or ammonium persulfate as an initiator is typically employed. Tetramethylethylenediamine (TMEDA or TEMED) may be and generally is used to accelerate the polymerisation.
- TEDA or TEMED Tetramethylethylenediamine
- hydrogels in producing hydrogels according to this invention, only one compound of formulae (I) or (II) will be used.
- Use of a compound of the formulae (I) or (II) permits formation of a hydrogel capable of being immobilised to solid supports, preferably silica-based solid supports.
- the compounds of these formulae comprise portions A, B and C as defined herein.
- Biradical A may be oxygen or N(R) wherein R is hydrogen or a C 1-5 alkyl group.
- R is hydrogen or methyl, particularly hydrogen.
- R is a C 1-5 alkyl group, this may contain one or more, e.g. one to three substituents.
- the alkyl group is unsubstituted.
- Biradical B is a predominantly hydrophobic linking moiety, connecting A to C and may be an alkylene biradical of formula —(CH 2 ) n —, wherein n is from 1 to 50.
- n is 2 or more, e.g. 3 or more.
- n is 2 to 25, particularly 2 to 15, more particularly 4 to 12, for example 5 to 10.
- one or more biradicals —CH 2 CH 2 — (-ethylene-) may be replaced with ethenylene or ethynylene biradicals.
- the biradical B does not contain such unsaturation.
- one or more methylene radicals —CH 2 — in B may be replaced with a mono- or polycyclic biradical which preferably comprises 5 to 10 carbon atoms e.g. 5 or 6 carbon atoms.
- cyclic biradicals may be, for example, 1,4-, 1,3- or 1,2-cyclohexyl biradicals.
- Bicylic radicals such as napthyl or decahydronaphthyl may also be employed.
- Corresponding heteroatom-substituted cyclic biradicals to those homocyclic biradicals may also be employed, for example pyridyl, piperidinyl, quinolinyl and decahydroquinolinyl.
- —B— is a simple, unsubstituted, unsaturated alkylene biradical such as a C 3 -C 10 alkylene group, optimally C 5 -C 8 , such as n-pentylene: —(CH 2 ) 5 —.
- substituents may be selected from the group comprising hydroxyl, halo (i.e. bromo, chloro, fluoro or iodo), carboxyl, aldehydro, amine and the like.
- the biradical —B— is preferably unsubstituted or substituted by fewer than 10, preferably fewer than 5, e.g. by 1, 2 or 3 such substituents.
- Group C serves to permit attachment of molecules of interest after formation of the hydrogel.
- the nature of Group C is thus essentially unlimited provided that it contains a functionality allowing reaction between the hydrogel and the molecules to be immobilised.
- a functionality will not require modification prior to reaction with the molecule of interest and thus the C group is ready for direct reaction upon formation of the hydrogel.
- a functionality is a hydroxyl, thiol, amine, acid (e.g. carboxylic acid), ester and haloacetamido, haloacetamido and in particular bromoacetamido being particularly preferred.
- Other appropriate C groups will be evident to those skilled in the art and include groups comprising a single carbon-carbon double bond which is either terminal (i.e.
- a C group has an extremity terminating in a carbon-carbon double bond) or where the carbon-carbon double bond is not at a terminal extremity.
- a C group comprises a carbon-carbon double bond, this is preferably fully substituted with C 1-5 alkyl groups, preferably methyl or ethyl groups, so that neither carbon atom of the C ⁇ C moiety bears a hydrogen atom.
- the C moiety may thus comprise, for example, a dimethylmaleimide moiety as disclosed in U.S. Pat. No. 6,372,813, WO01/01143, WO02/12566 and WO03/014394.
- the (meth)acrylamide or (meth)acrylate of formula (I) or (II) which is copolymerised with acrylamide, methacrylamide, hydroxyethyl methacrylate or N-vinyl pyrrolidinone is preferably an acrylamide or acrylate, i.e. of formula (I). More preferably it is an acrylamide and still more preferably it is an acrylamide in which A is NH.
- Control of the proportion of monomer of formula (I) or (II) to that of the first comonomer allows adjustment of the physical properties of the hydrogel obtained on polymerisation. It is preferred that the comonomer of formula (I) or (II) is present in an amount of ⁇ 1 mol %, preferably ⁇ 2 mol % (relative to the total molar quantity of comonomers) in order for the hydrogel to have optimum thermal and chemical stability under conditions typically encountered during the preparation, and subsequent manipulation, of the molecular arrays produced from the hydrogels.
- the first comonomer e.g. acrylamide and/or methacrylamide, preferably acrylamide
- the amount of comonomer of formula (I) or (II) is less than or equal to about 5 mol %, more preferably less than or equal to about 4 mol %.
- Typical amounts of comonomer of formula (I) or (II) used are 1.5-3.5 mol %, exemplified herein by about 2% and about 3%.
- the amounts of acrylamide or methacrylamide from which the hydrogels are primarily constructed are those typically used to form hydrogels, e.g. about 1 to about 10% w/v, preferably less than 5 or 6% w/v, e.g. about 1 to about 2% w/v. Again, of course, the precise nature of the hydrogel may be adjusted by, in part, control of the amount of acrylamide or methacrylamide used.
- acrylamide or methacrylamide may be dissolved in water and mixed with a solution of a comonomer of formula (I) or (II).
- a comonomer of formula (I) or (II) may be conveniently dissolved in a water-miscible solvent, such as dimethylformamide (DMF), or water itself.
- DMF dimethylformamide
- the most appropriate solvent may be selected by the skilled person and shall depend upon the structure of the comonomer of formula (I) or (II).
- the general methods by which the polymerisation is carried out are known to those skilled in the art.
- acrylamide or methacrylamide is dissolved in purified water (e.g. Milli Q) and potassium or ammonium persulfate dissolved separately in purified water.
- the comonomer of formula (I) or (II) may be conveniently dissolved in a water-miscible organic solvent, e.g. glycerol, ethanol, methanol, dimethylformamide (DMF) etc.
- TEMED may be added as appropriate.
- the polymerisation process may be conducted by any convenient means.
- the second aspect of the invention is not limited with respect to the nature of the solid support and can be used in conjunction with essentially any type of support known in the art for production of polynucleotide arrays, and more specifically with any type of support which is compatible with solid-phase nucleic acid amplification.
- Suitable supports include those coated with functionalised silanes.
- the method of the second aspect of the invention can be used in conjunction with the silane-coated solid supports described in WO 98/44151 and WO 00/18957.
- the methods according to the first and second aspects of the invention may be used to prepare templates for sequencing starting from double-stranded nucleic acid molecules present in clustered arrays of nucleic acid colonies generated by solid-phase nucleic acid amplification.
- solid-phase amplification refers to an amplification reaction which is analogous to standard PCR, except that the forward and reverse amplification primers are immobilised (e.g. covalently attached) to a solid support at or near the 5′ end.
- the products of the PCR reaction are thus extended strands derived by extension of the amplification primers that are immobilised on the solid support at or near the 5′ end.
- Solid-phase amplification may itself be carried out, for example, using procedures analogous to those described in WO 98/44151 and WO 00/18957, the contents of which are incorporated herein in their entirety by reference.
- a mixture of forward and reverse amplification primers may be immobilised or “grafted” onto the surface of a suitable solid support.
- the grafting step will generally involve covalent attachment of the primers to the support at or near the 5′ end, leaving the 3′ end free for primer extension.
- the amplification primers are typically oligonucleotide molecules have the following structures:
- A represents a moiety which allows attachment to a solid support
- L represents an optional linker moiety
- S1 and S2 are polynucleotide sequences which permit amplification of a substrate nucleic acid molecule comprising a target region that it is desired to (fully or partially) sequence.
- the mixture of primers grafted onto the solid support will generally comprise substantially equal amounts of the forward and reverse primers.
- Group A can be any moiety (including a non-nucleotide chemical modification) which enables attachment (preferably covalent) to a solid support.
- group A may comprise a sulphur-containing nucleophile, such as phosphorothioate, present at the 5′ end of a polynucleotide strand.
- the most preferred means of grafting primers to a solid support is via 5′ phosphorothioate attachment to a hydrogel comprised of polymerised acrylamide and N-(5-bromoacetamidylpentyl)acrylamide (BRAPA).
- L represents a linker or spacer which may be included but is not strictly necessary.
- the linker may be included in order to ensure that a cleavage site present in the immobilised polynucleotide molecules generated as a result of the amplification reaction is positioned at an optimum distance from the solid support, or the linker may itself contain a cleavage site.
- the linker may be a carbon-containing chain such as those of formula (CH 2 ) n wherein “n” is from 1 to about 1500, for example less than about 1000, preferably less than 100, e.g. from 2-50, particularly 5-25.
- n is from 1 to about 1500, for example less than about 1000, preferably less than 100, e.g. from 2-50, particularly 5-25.
- linkers may be employed with the only restriction placed on their structures being that the linkers are stable under conditions under which the polynucleotides are intended to be used subsequently, e.g. conditions used in DNA amplification, cleavage and sequencing.
- Linkers which do not consist of only carbon atoms may also be used. Such linkers include polyethylene glycol (PEG) having a general formula of (CH 2 —CH 2 —O) m , wherein m is from about 1 to 600, preferably less than about 500.
- PEG polyethylene glycol
- Linkers formed primarily from chains of carbon atoms and from PEG may be modified so as to contain functional groups which interrupt the chains. Examples of such groups include ketones, esters, amines, amides, ethers, thioethers, sulfoxides, sulfones. Separately or in combination with the presence of such functional groups may be employed alkene, alkyne, aromatic or heteroaromatic moieties, or cyclic aliphatic moieties (e.g. cyclohexyl). Cyclohexyl or phenyl rings may, for example, be connected to a PEG or (CH 2 ) n chain through their 1- and 4-positions.
- linkers described above which are primarily based on linear chains of saturated carbon atoms, optionally interrupted with unsaturated carbon atoms or heteroatoms
- other linkers may be envisaged which are based on nucleic acids or monosaccharide units (e.g. dextrose). It is also within the scope of this invention to utilise peptides as linkers.
- the linker may comprise one or more nucleotides.
- nucleotides may also be referred to herein as “spacer” nucleotides.
- spacer nucleotides
- the primer will include 10 spacer nucleotides. It is preferred to use polyT spacers, although other nucleotides and combinations thereof can be used.
- the primer may include 10T spacer nucleotides.
- a mixture of the amplification primers is applied to a solid support under conditions which permit reaction between moiety A and the support.
- the solid support may be suitably functionalised to permit covalent attachment via moiety A.
- the result of the grafting reaction is a substantially even distribution of the primers over the solid support.
- the template to be amplified may be grafted onto the solid support together with the amplification primers in a single grafting reaction. This can be achieved by adding template molecules including moiety A at the 5′ end to the mixture of primers to form a primer-template mixture. This mixture is then grafted onto the solid support in a single step. Amplification may then proceed using the immobilised template and primers in a reaction analogous to that described in WO 00/18957. The first step in such a reaction will be hybridisation between surface-bound templates and surface-bound amplification primers.
- the template to be amplified may be added in free solution.
- the amplification reaction may then proceed substantially as described in WO 98/44151. Briefly, following attachment of the primers the solid support is contacted with the template to be amplified under conditions which permit hybridisation between the template and the immobilised primers.
- the template is usually added in free solution under suitable hybridisation conditions, which will be apparent to the skilled reader. Typically hybridisation conditions are, for example, 5 ⁇ SSC at 40° C., following an initial denaturation step.
- Solid-phase amplification can then proceed, the first step of the amplification being a primer extension step in which nucleotides are added to the 3′ end of the immobilised primer hybridised to the template to produce a fully extended complementary strand.
- This complementary strand will thus include at its 3′ end a sequence which is capable of binding to the second primer molecule immobilised on the solid support. Further rounds of amplification (analogous to a standard PCR reaction) lead to the formation of clusters or colonies of template molecules bound to the solid support.
- Sequences S1 and S2 in the amplification primers may be specific for a particular target nucleic acid that it is desired to amplify, but in other embodiments sequences S1 and S2 may be “universal” primer sequences which enable amplification of any target nucleic acid of known or unknown sequence which has been modified to enable amplification with the universal primers.
- Suitable substrates to be amplified with universal primers may be prepared by modifying polynucleotides comprising the target region to be amplified (and sequenced) by addition of known adaptor sequences to the 5′ and 3′ ends of the target polynucleotides to be amplified.
- the target molecules themselves may be any double-stranded polynucleotide molecules it is desired to sequence (e.g. random fragments of human genomic DNA).
- the adaptor sequences enable amplification of these molecules on a solid support to form clusters using forward and reverse primers having the general structure described above, wherein sequences S1 and S2 are universal primer sequences.
- the adaptors are typically short oligonucleotides that may be synthesised by conventional means.
- the adaptors may be attached to the 5′ and 3′ ends of target nucleic acid fragments by a variety of means (e.g. subcloning, ligation. etc). More specifically, two different adaptor sequences are attached to a target nucleic acid molecule to be amplified such that one adaptor is attached at one end of the target nucleic acid molecule and another adaptor is attached at the other end of the target nucleic acid molecule.
- the resultant construct comprising a target nucleic acid sequence flanked by adaptors may be referred to herein as a “substrate nucleic acid construct”.
- the target polynucleotides may advantageously be size-fractionated prior to modification with the adaptor sequences.
- the adaptors contain sequences which permit nucleic acid amplification using the amplification primer molecules immobilised on the solid support. These sequences in the adaptors may be referred to herein as “primer binding sequences”.
- primer binding sequences In order to act as a template for nucleic acid amplification, a single strand of the template construct must contain a sequence which is complementary to sequence S1 in the forward amplification primers (such that the forward primer molecule can bind and prime synthesis of a complementary strand) and a sequence which corresponds to sequence S2 in the reverse amplification primer molecules (such that the reverse primer molecule can bind to the complementary strand).
- the sequences in the adaptors which permit hybridisation to primer molecules will typically be around 20-40 nucleotides in length, although the invention is not limited to sequences of this length.
- sequences S1 and S2 in the amplification primers are generally not material to the invention, as long as the primer molecules are able to interact with the amplification sequences in order to direct PCR amplification.
- the criteria for design of PCR primers are generally well known to those of ordinary skill in the art.
- Solid-phase amplification by either the method analogous to that of WO 98/44151 or that of WO 00/18957 will result in production of a clustered array comprised of colonies of “bridged” amplification products. Both strands of the amplification products will be immobilised on the solid support at or near the 5′ end, this attachment being derived from the original attachment of the amplification primers. Typically the amplification products within each colony will be derived from amplification of a single template (target) molecule.
- Modifications required to enable subsequent cleavage of the bridged amplification products may be advantageously included in one or both amplification primers. Such modifications may be placed anywhere in the amplification primer, provided this does not affect the efficiency of the amplification reaction to a material extent. Thus, the modifications which enable cleavage may form part of the linker region L or one or both of sequences S1 or S2.
- the amplification primers may be modified to include inter alia diol linkages, uracil nucleotides, ribonucleotides, methylated nucleotides, peptide linkers, PCR stoppers or recognition sequences for a restriction endonuclease. Because all nucleic acid molecules prepared by solid-phase amplification will ultimately contain sequences derived from the amplification primers, any modifications in the primers will be carried over into the amplified products.
- the invention provides a method of solid-phase nucleic acid amplification wherein forward and reverse amplification primers covalently attached to a solid support at the 5′ end are used to amplify one or more polynucleotide templates, the method being characterised in that one or both of the amplification primers includes a site for cleavage by a method other than digestion with the restriction endonuclease or a nicking endonuclease.
- Preferred features of the amplification primers are as described above and preferred cleavage methods are as described above in connection with the first and second aspects of the invention.
- Other preferred features described in relation to the first and second aspects of the invention apply mutatis mutandis to this aspect of the invention.
- the utility of the “template formation” method of the first and second aspects of the invention is not limited to formation of templates from double-stranded nucleic acids produced by an amplification reaction, although this is preferred.
- the method may be applied to linearisation of immobilised double-stranded polynucleotides produced on a support by any other means.
- the invention also encompasses method of sequencing nucleic acid templates generated using the methods of the invention.
- the invention provides a method of nucleic acid sequencing comprising forming a template for nucleic acid sequencing using a method according to the first or second aspect of the invention and performing a nucleic acid sequencing reaction to determine the sequence one at least one region of the template.
- Sequencing can be carried out using any suitable “sequencing-by-synthesis” technique, wherein nucleotides are added successively to a free 3′ hydroxyl group, resulting in synthesis of a polynucleotide chain in the 5′ to 31 direction.
- the nature of the nucleotide added is preferably determined after each addition.
- an initiation point for a sequencing reaction may be provided by annealing of a sequencing primer to a single-stranded region of the template.
- the invention encompasses methods wherein the nucleic acid sequencing reaction comprises hybridising a sequencing primer to a single-stranded region of the template generated in step (iii) of the “template generation” method of the first or second aspect of the invention, sequentially incorporating one or more nucleotides into a polynucleotide strand complementary to the region of the template to be sequenced, identifying the base present in one or more of the incorporated nucleotide(s) and thereby determining the sequence of a region of the template.
- the initiation point for the sequencing reaction may be a free 3′ hydroxyl group generated by cleavage of one strand of the template itself (e.g. by cleavage of an abasic nucleotide with endonuclease, heat or alkali).
- the invention also provides methods of sequencing which involve forming a template for nucleic acid sequencing using a method comprising steps (i) and (ii) only of the “template formation” methods of the first or second aspects of the invention, carrying out a strand displacement sequencing reaction by sequentially adding one or more nucleotides to a free 3′ hydroxyl group generated on the strand cleaved in step (ii), identifying the base present in one or more of the incorporated nucleotide(s) and thereby determining the sequence of a region of the template.
- a preferred sequencing method which can be used in all aspects of the invention relies on the use of modified nucleotides containing 3′ blocking groups that can act as chain terminators. Once the modified nucleotide has been incorporated into the growing polynucleotide chain complementary to the region of the template being sequenced there is no free 3′-OH group available to direct further sequence extension and therefore the polymerase can not add further nucleotides. Once the nature of the base incorporated into the growing chain has been determined, the 3′ block may be removed to allow addition of the next successive nucleotide. By ordering the products derived using these modified nucleotides it is possible to deduce the DNA sequence of the DNA template.
- Such reactions can be done in a single experiment if each of the modified nucleotides has attached a different label, known to correspond to the particular base, to facilitate discrimination between the bases added at each incorporation step.
- a separate reaction may be carried out containing each of the modified nucleotides separately.
- the modified nucleotides may carry a label to facilitate their detection.
- this is a fluorescent label.
- Each nucleotide type may carry a different fluorescent label.
- the detectable label need not be a fluorescent label. Any label can be used which allows the detection of an incorporated nucleotide.
- One method for detecting fluorescently labelled nucleotides comprises using laser light of a wavelength specific for the labelled nucleotides, or the use of other suitable sources of illumination.
- the fluorescence from the label on the nucleotide may be detected by a CCD camera or other suitable detection means.
- the methods of the invention are not limited to use of the sequencing method outlined above, but can be used in conjunction with essentially any sequencing methodology which relies on successive incorporation of nucleotides into a polynucleotide chain.
- Suitable techniques include, for example, PyrosequencingTM, FISSEQ (fluorescent in situ sequencing), MPSS (massively parallel signature sequencing) and sequencing by ligation-based methods.
- the target polynucleotide to be sequenced using the method of the invention may be any polynucleotide that it is desired to sequence.
- the target polynucleotide may be of known, unknown or partially known sequence, for example in re-sequencing applications.
- Using the template preparation method described in detail herein it is possible to prepare templates starting from essentially any double-stranded target polynucleotide of known, unknown or partially known sequence. With the use of arrays it is possible to sequence multiple targets of the same or different sequence in parallel.
- a particularly preferred application of the method is in the sequencing of fragments of genomic DNA.
- the solid supports used in this experiment were 8-channel glass chips such as those provided by Micronit (Twente, Nederland) or IMT (Neuchatel, Switzerland). However, the experimental conditions and procedures are readily applicable to other solid supports.
- Chips were washed as follows: neat Decon for 30 min, milliQ H 2 O for 30 min, NaOH 1N for 15 min, milliQ H 2 O for 30 min, HCl 0.1N for 15 min, milliQ H 2 O for 30 min.
- the 10 ml solution of acrylamide was first degassed with argon for 15 min.
- the solutions of BRAPA, TEMED and potassium persulfate were successively added to the acrylamide solution.
- the mixture was then quickly vortexed and immediately used. Polymerization was then carried out for 1 h 30 at RT. Afterwards the channels were washed with milliQ H 2 O for 30 min.
- the slide was then dried by flushing argon through the inlets and stored under low pressure in a dessicator.
- N-Boc-1,5-diaminopentane toluene sulfonic acid was obtained from Novabiochem.
- the bromoacetyl chloride and acryloyl chloride were obtained from Fluka. All other reagents were Aldrich products.
- the primers were 5′-phosphorothioate oligonucleotides. Their sequences and suppliers varied according to the experiment they were used for (see specific examples).
- Grafting was carried out using 80 ⁇ l per channel in 10 mM phosphate buffer pH7 for 1 h at RT.
- a PCR template may be hybridised to the grafted primers immediately prior to the PCR reaction.
- the PCR reaction thus begins with an initial primer extension step rather than template denaturation.
- the hybridization procedure begins with a heating step in a stringent buffer (95° C. for 5 minutes in TE) to ensure complete denaturation prior to hybridisation of the PCR template. Hybridization was then carried out in 5 ⁇ SSC, using template diluted to the desired final concentration. After the hybridization, the chip was washed for 5 minutes with milliQ water to remove salts.
- thermocycled PCR was carried out by thermocycled PCR in an MJ Research thermocycler.
- a typical PCR program is as follows:
- the first step in the amplification reaction was extension of the primers bound to template in the initial hybridisation step the first denaturation and annealing steps of this program are omitted (i.e. the chip is placed on the heating block only when the PCR mix is pumped through the flow cell and the temperature is at 73° C.).
- the annealing temperature (X° C., step 2) depends on the primer pair that is used. Experiments have determined an optimal annealing temperature of 57° C. for P5/P7 primers. For other primer-pairs the optimum annealing temperature can be determined by experiment. The number of PCR cycles may be varied if required.
- PCR was carried out in a reaction solution comprising 1 ⁇ PCR reaction buffer (supplied with the enzyme) 1M betain, 1.3% DMSO, 200 ⁇ M dNTPs and 0.025 U/ ⁇ L Taq polymerase.
- the procedure begins with a heating step in a stringent buffer (TE) to ensure complete denaturation of the colonies prior to hybridisation of the primer.
- TE stringent buffer
- Hybridization was carried out in 5 ⁇ SSC, using an oligonucleotide diluted to a final concentration of 500 nM. This solution should be prepared just before use, especially when fluorophore-labelled oligonucleotides are used.
- Typical temperature cycling profile was as follows:
- Grafting was performed according to the procedure described under general methods. Channels 1 and 2 of an 8 channel chip were grafted using the non-cleavable primer, channels 5, 6 and 7 using the cleavable diol linker and channel 8 using the grafting control.
- a first hybridization using the complementary P5 oligonucleotide (SEQ ID NO:1) was performed to measure the percentage of P5 oligonucleotides attached to the surface. Standard hybridisation conditions are described in the general methods above. Channels to be cleaved were treated with a solution of 0.1M sodium periodate in water for 30 min at room temperature, channel 1 being kept as a control to evaluate the potential damage of the DNA or the surface by sodium periodate. The channels were then washed for 5 minutes with milliQ water then 5 min 5 ⁇ SSC buffer at room temperature.
- a second hybridization was carried out using the complementary P5 oligonucleotide (SEQ ID NO:1) to evaluate the percentage of non-cleaved oligonucleotide.
- a second treatment with 0.1M sodium periodate was then performed for 15 min followed by the same washing conditions and a last hybridization using the complementary PS oligonucleotide.
- the chip was scanned using the following settings: focal plane +3 mm, 600V, 610BP/Red (633 nm). The intensities were then normalized.
- the linker unit is incorporated with the diol in a protected OAc form during oligonucleotide synthesis.
- the free diol is released by ammonia treatment during oligonucleotide cleavage/deprotection. Therefore, the primers used in the grafting reaction contain the free diol.
- the template used for amplification was a library of PCR fragments derived from PhiX 174.
- the fragments contain common “end” sequences enabling amplification with the P5 and P7 primers flanking 400-700 bp fragments of PhiX 174 of unknown sequence.
- Hybridization of the template was carried out substantially as described in the general methods above using a 100 ⁇ M solution of template for channels 2, 3, 4, 5, 6 and 7, channels 1 and 8 being kept as primer only controls.
- PCR was performed as described in the general methods. Amplification products were then stained with SyBr Green-I in TE buffer (1/10 000), using 100 ⁇ l per channel and visualised using objective 0.4, Filter Xf 22 and 1 second acquisition time (gain 1).
- FIGS. 5 and 6 illustrate that successful colony formation was obtained using the cleavable diol primer.
- Channels to be cleaved were treated with a solution of 0.1M of sodium periodate and 0.1M ethanolamine in water for 1 hour at room temperature. All the other channels were washed with milliQ water. All channels were then washed for 30 minutes with milliQ water at room temperature.
- Hybridization was carried out using the sequencing primer (SEQ ID NO:6) labelled with A594 to evaluate the percentage of non-cleaved oligonucleotide.
- the sequencing primer was hybridised to the linearised clusters prepared as described above at 500 nM, using standard conditions for hybridisation as described under the general methods.
- the chip was then imaged using an orange filter with an exposure time of 1 s.
- the channels grafted with the non-cleavable primers did not give any hybridization signal with the sequencing primer. As the colonies in these channels are still double-stranded no hybridization of the sequencing primer can occur.
- Hybridization of the sequencing primer was detected in the two diol channels treated with sodium periodate.
- the solid supports used were typically 8-channel glass flowcells such as those provided by Silex Microsystems (Sweden). However, the experimental conditions and procedures are readily applicable to other solid supports.
- FIG. 7 A schematic representation of one such flowcell is shown in FIG. 7 .
- the flowcell is formed in three layers.
- the bottom layer 1 is formed of borosilicate glass at a depth of 1000 ⁇ m.
- An etched silicon channel layer (100 ⁇ m depth) is placed on top to defined 8 separate reaction channels.
- Top layer 3 (300 ⁇ m depth) includes two separate series of 8 holes 4 and 4′ in register with the channels of the etched silicon channel layer in order to provide fluid communication with the contents of the channels when the flowcell is assembled in use.
- Flowcells were washed as follows: neat Decon for 30 min, milliQ H 2 O for 30 min, NaOH 1N for 15 min, milliQ H 2 O for 30 min, HCl 0.1N for 15 min, milliQ H 2 O for 30 min.
- the 10 ml solution of acrylamide was first degassed with argon for 15 min.
- the solutions of BRAPA, TEMED and potassium persulfate were successively added to the acrylamide solution.
- the mixture was then quickly vortexed and immediately pumped into the flowcell. Polymerization was then carried out for 1 h 30 at RT. Afterwards the channels were washed with milliQ H 2 O for 30 min and filled with 0.1 M potassium phosphate buffer for storage until required.
- An acrylamide (SFA) coated flowcell was placed onto a modified MJ-Research thermocycler and attached to a peristaltic pump. Grafting mix consisting of 0.5 ⁇ M of a forward primer and 0.5 ⁇ M of a reverse primer in 10 mM phosphate buffer (pH 7.0) was pumped into the channels of the flowcell at a flow rate of 60 ⁇ l/min for 75 s at 20° C. The thermocycler was then heated up to 51.6° C., and the flowcell incubated at this temperature for 1 hour.
- SFA acrylamide
- the grafting mix underwent 18 cycles of pumping: grafting mix was pumped in at 15 ⁇ l/min for 20 s, then the solution was pumped back and forth (5 s forward at 15 ⁇ l/min, then 5 s backward at 15 ⁇ l/min) for 180 s. After 18 cycles of pumping, the flowcell was washed by pumping in 5 ⁇ SSC/5 mM EDTA at 15 ⁇ l/min for 300 s at 51.6° C. The thermocycler was then cooled to 20° C.
- the primers were typically 5′-phosphorothioate oligonucleotides incorporating any specific sequences or modifications required for cleavage. Their sequences and suppliers varied according to the experiment they were to be used for, and in this case were complementary to the 5′-ends of the template duplex.
- the amplified clusters contained a diol linkage in one of the grafted primers. Diol linkages can be introduced by including a suitable linkage into one of the primers used for solid-phase amplification.
- the grafted primers contained a sequence of T bases at the 5′-end to act as a spacer group to aid linearisation and hybridization. Synthesis of the diol phosphoramidite is detailed below. Oligonucleotides were prepared using the diol phosphoramidite using standard coupling conditions on a commercial DNA synthesiser. The final cleavage/deprotection step in ammonia cleaves the acetate groups from the protected diol moiety, so that the oligonucleotide in solution contains the diol modification.
- the sequences of the two primers grafted to the flowcell are:
- 1,6-Hexanediol (Sigma Aldrich 99%) (14.6 g, 124 mmol), N,N-diisopropylethylamine (Hünig's base; Sigma Aldrich; redistilled) (21.6 mL, 124 mmol) was dissolved in anhydrous DCM/DMF (250/50 mL) under N 2 . The solution was cooled to 0° C. and the first portion of 4,4′-dimethoxytrityl chloride (DMTr-Cl; Sigma-Aldrich 95%) (10.5 g, 31 mmol) added. The reaction mixture was then warmed to room temperature. After stirring for 1 h, the reaction mixture was cooled to 0° C.
- DMTr-Cl 4,4′-dimethoxytrityl chloride
- the reaction mixture was pre-absorbed on silica gel and subjected to flash chromatography using solvents containing 1% Et 3 N petroleum ether to petroleum ether/EtOAc (7:3) as eluent.
- the yield of pale yellow oil was 16.58 g, 64%, with a further 7.8 g (17%) of the bis-tritylated by-product.
- triphenylphosphine (Sigma-Aldrich 99%, ReagentPlusTM). (39.3 g, 150 mmol) and 4-bromobutyl acetate (Sigma-Aldrich)(26 mL, 180 mmol) in anhydrous toluene (300 mL) was heated under reflux for 36 hours under N 2 in an oil-bath (140° C.). During the reflux, oil was precipitated out. The reaction mixture was cooled to room temperature. TLC (petroleum ether/EtOAc 7:3) analysis of the toluene solution showed that there was still triphenylphosphine (R f : 0.8) left.
- TLC petroleum ether/EtOAc 7:3
- Diol-2 (10.34 g, 22.7 mmol) was weighed into a round-bottomed flask and dissolved with DCM (20 mL). The solution was then evaporated under reduced pressure until it gave a white foam. The flask was then subjected to high vacuum for 24 h. To this flask, anhydrous THF (180 mL) was added under N 2 . The resulting suspension was cooled to ⁇ 78° C. with an acetone-dry ice bath. With vigorous stirring, KOBu t (3.3 g, 29.5 mmol) was added under N 2 . Slowly the colour of the suspension turned orange, and white solids were gradually precipitated out. To this suspension, a solution of diol-3 (dried at 60° C.
- the DNA sequence used in the amplification process was a single monotemplate sequence of 364 bases, with ends complimentary to the grafted primers.
- the full sequence of the template duplex is shown in FIG. 8 (SEQ ID NO:8).
- the duplex DNA (1 nM) was denatured using 0.1 M sodium hydroxide treatment followed by snap dilution to the desired 0.2-2 pM ‘working concentration’ in ‘hybridization buffer’ (5 ⁇ SSC/0.1% tween).
- thermocycling using an MJ Research thermocycler, coupled with an 8-way peristaltic pump Ismatec IPC ISM931 equipped with Ismatec tubing (orange/yellow, 0.51 mm ID).
- the single stranded template was hybridised to the grafted primers immediately prior to the amplification reaction, which thus begins with an initial primer extension step rather than template denaturation.
- the hybridization procedure begins with a heating step in a stringent buffer to ensure complete denaturation prior to hybridisation. After the hybridization, which occurs during a 20 min slow cooling step, the flowcell was washed for 5 minutes with a wash buffer (0.3 ⁇ SSC/0.1% tween).
- the linearisation buffer consisted of 1429 ⁇ L of water, 64 mg of sodium periodate, 1500 ⁇ L of formamide, 60 ⁇ L of 1 M Tris pH 8, and 11.4 ⁇ L of 3-aminopropanol, mixed for a final volume of 3 mL.
- the periodate was first mixed with the water while the Tris was mixed with the formamide.
- the two solutions were then mixed together and the 3-aminopropanol added to that mixture.
- the computer component of the instrumentation flowed the appropriate blocking buffer through the flow cell, and controlled the temperature as shown in the exemplary embodiments below.
- the computer component of the instrumentation flowed the appropriate solutions through the flow cell as described below:
- the flowcell was ready for sequencing.
- a mutant 9° N polymerase enzyme (an exo-variant including the triple mutation L408Y/Y409A/P410V and C223S) was used for the nucleotide incorporation steps.
- Incorporation mix Incorporation buffer (50 mM Tris-HCl pH 8.0, 6 mM MgSO4, 1 mM EDTA, 0.05% (v/v) Tween ⁇ 20, 50 mM NaCl) plus 110 nM YAV exo-C223S, and 1 ⁇ M each of the four labelled modified nucleotides, was applied to the clustered templates, and heated to 45° C.
- Templates were maintained at 45° C. for 30 min, cooled to 20° C. and washed with Incorporation buffer, then with 5 ⁇ SSC/0.05% Tween 20. Templates were then exposed to Imaging buffer (100 mM Tris pH 7.0, 30 mM NaCl, 0.05% Tween 20, 50 mM sodium ascorbate, freshly dissolved).
- Imaging buffer 100 mM Tris pH 7.0, 30 mM NaCl, 0.05% Tween 20, 50 mM sodium ascorbate, freshly dissolved.
- Templates were scanned in 4 colours at room temp.
- nucleotides were detected using a total internal reflection based fluorescent CCD imaging apparatus. Images were recorded and analysed to measure the intensites and numbers of the fluorescent objects on the surface. Images of two tiles from the first cycle of nucleotide incorporation for a linearised and a non-linearised (no periodate) channel are shown in FIG. 9 . The histogram plots of these tiles are shown in FIG. 10 . In the case of the sequence selected for amplification, only a single base (T) was incorporated in each cluster. This figure clearly shows the presence of clusters in both the linearised and non linearised channels, but the linearised clusters show a far higher average signal intensity. In the absence of the linearisation step, the clusters remain double stranded, and can not undergo effective hybridisation with a sequencing primer, and therefore show greatly reduced signal upon treatment with nucleotides and polymerase.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0514936.4A GB0514936D0 (en) | 2005-07-20 | 2005-07-20 | Preparation of templates for nucleic acid sequencing |
GB0514936.4 | 2005-07-20 | ||
PCT/GB2006/002687 WO2007010251A2 (fr) | 2005-07-20 | 2006-07-20 | Preparation de matrices pour sequencage d'acides nucleiques |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/002687 A-371-Of-International WO2007010251A2 (fr) | 2005-07-20 | 2006-07-20 | Preparation de matrices pour sequencage d'acides nucleiques |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/450,920 Continuation US8715966B2 (en) | 2005-07-20 | 2012-04-19 | Preparation of templates for nucleic acid sequencing |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090118128A1 true US20090118128A1 (en) | 2009-05-07 |
Family
ID=34897551
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/989,169 Abandoned US20090118128A1 (en) | 2005-07-20 | 2006-07-20 | Preparation of templates for nucleic acid sequencing |
US13/450,920 Active US8715966B2 (en) | 2005-07-20 | 2012-04-19 | Preparation of templates for nucleic acid sequencing |
US14/166,670 Active US9085802B2 (en) | 2005-07-20 | 2014-01-28 | Preparation of templates for nucleic acid sequencing |
US14/738,591 Active US9498763B2 (en) | 2005-07-20 | 2015-06-12 | Preparation of templates for nucleic acid sequencing |
US15/287,077 Active US9999866B2 (en) | 2005-07-20 | 2016-10-06 | Preparation of templates for nucleic acid sequencing |
US16/010,902 Active US10710046B2 (en) | 2005-07-20 | 2018-06-18 | Preparation of templates for nucleic acid sequencing |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/450,920 Active US8715966B2 (en) | 2005-07-20 | 2012-04-19 | Preparation of templates for nucleic acid sequencing |
US14/166,670 Active US9085802B2 (en) | 2005-07-20 | 2014-01-28 | Preparation of templates for nucleic acid sequencing |
US14/738,591 Active US9498763B2 (en) | 2005-07-20 | 2015-06-12 | Preparation of templates for nucleic acid sequencing |
US15/287,077 Active US9999866B2 (en) | 2005-07-20 | 2016-10-06 | Preparation of templates for nucleic acid sequencing |
US16/010,902 Active US10710046B2 (en) | 2005-07-20 | 2018-06-18 | Preparation of templates for nucleic acid sequencing |
Country Status (6)
Country | Link |
---|---|
US (6) | US20090118128A1 (fr) |
EP (2) | EP1910559B1 (fr) |
ES (1) | ES2398808T5 (fr) |
GB (1) | GB0514936D0 (fr) |
HK (1) | HK1154636A1 (fr) |
WO (1) | WO2007010251A2 (fr) |
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012025250A1 (fr) | 2010-08-27 | 2012-03-01 | Illumina Cambridge Ltd. | Méthodes de séquençage de polynucléotides |
US8198028B2 (en) | 2008-07-02 | 2012-06-12 | Illumina Cambridge Limited | Using populations of beads for the fabrication of arrays on surfaces |
WO2013126741A1 (fr) | 2012-02-24 | 2013-08-29 | Raindance Technologies, Inc. | Marquage et préparation d'échantillon pour le séquençage |
US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
US8535889B2 (en) | 2010-02-12 | 2013-09-17 | Raindance Technologies, Inc. | Digital analyte analysis |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
EP2669387A1 (fr) | 2009-08-25 | 2013-12-04 | Illumina, Inc. | Procédés de sélection et d'amplification de polynucléotides |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US8759037B2 (en) | 2010-02-23 | 2014-06-24 | Illumina Cambridge Limited | Amplification methods to minimise sequence specific bias |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US8871444B2 (en) | 2004-10-08 | 2014-10-28 | Medical Research Council | In vitro evolution in microfluidic systems |
US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
WO2015108663A1 (fr) | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Préparation et séquençage d'amplicons sur supports solides |
US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
US9273308B2 (en) | 2006-05-11 | 2016-03-01 | Raindance Technologies, Inc. | Selection of compartmentalized screening method |
US9328344B2 (en) | 2006-01-11 | 2016-05-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9448172B2 (en) | 2003-03-31 | 2016-09-20 | Medical Research Council | Selection by compartmentalised screening |
US9498759B2 (en) | 2004-10-12 | 2016-11-22 | President And Fellows Of Harvard College | Compartmentalized screening by microfluidic control |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
WO2017168332A1 (fr) | 2016-03-28 | 2017-10-05 | Boreal Genomics, Inc. | Capture de cible duplex liée |
US9839890B2 (en) | 2004-03-31 | 2017-12-12 | National Science Foundation | Compartmentalised combinatorial chemistry by microfluidic control |
CN107849598A (zh) * | 2015-05-29 | 2018-03-27 | 伊卢米纳剑桥有限公司 | 簇中的表面引物的增强利用 |
US10000799B2 (en) | 2014-11-04 | 2018-06-19 | Boreal Genomics, Inc. | Methods of sequencing with linked fragments |
US9999866B2 (en) | 2005-07-20 | 2018-06-19 | Illumina Cambridge Limited | Preparation of templates for nucleic acid sequencing |
WO2018119057A2 (fr) | 2016-12-22 | 2018-06-28 | Illumina, Inc. | Réseau comprenant une amorce de séquençage et une entité non de séquençage |
US10036063B2 (en) | 2009-07-24 | 2018-07-31 | Illumina, Inc. | Method for sequencing a polynucleotide template |
US10052605B2 (en) | 2003-03-31 | 2018-08-21 | Medical Research Council | Method of synthesis and testing of combinatorial libraries using microcapsules |
US20180265660A1 (en) * | 2013-07-01 | 2018-09-20 | Illumina, Inc. | Catalyst-free surface functionalization and polymer grafting |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
WO2019222264A1 (fr) | 2018-05-15 | 2019-11-21 | Illumina, Inc. | Compositions, procédés de clivage chimique et procédés de déprotection d'oligonucléotides liés à une surface |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US10537889B2 (en) | 2013-12-31 | 2020-01-21 | Illumina, Inc. | Addressable flow cell using patterned electrodes |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
WO2020136170A2 (fr) | 2018-12-26 | 2020-07-02 | Illumina Cambridge Limited | Nucléosides et nucléotides avec des groupes de blocage 3'-hydroxy |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US10961573B2 (en) | 2016-03-28 | 2021-03-30 | Boreal Genomics, Inc. | Linked duplex target capture |
WO2021167986A1 (fr) | 2020-02-17 | 2021-08-26 | 10X Genomics, Inc. | Analyse in situ de l'interaction chromatinienne |
US11174509B2 (en) | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
WO2021259881A1 (fr) | 2020-06-22 | 2021-12-30 | Illumina Cambridge Limited | Nucléosides et nucléotides avec groupe de blocage acétal 3' |
US11214798B2 (en) * | 2014-09-09 | 2022-01-04 | Igenomx International Genomics Corporation | Methods and compositions for rapid nucleic acid library preparation |
US11268137B2 (en) | 2016-12-09 | 2022-03-08 | Boreal Genomics, Inc. | Linked ligation |
CN114457146A (zh) * | 2022-01-28 | 2022-05-10 | 赛纳生物科技(北京)有限公司 | 一种固相介质表面双端扩增测序的方法 |
US11359238B2 (en) | 2020-03-06 | 2022-06-14 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
WO2022159474A1 (fr) | 2021-01-19 | 2022-07-28 | 10X Genomics, Inc. | Procédés et compositions pour dosages in situ par étalon interne |
WO2022187366A1 (fr) | 2021-03-03 | 2022-09-09 | 10X Genomics, Inc. | Détection d'analytes in situ à l'aide d'origami d'acide nucléique |
US11473136B2 (en) | 2019-01-03 | 2022-10-18 | Ncan Genomics, Inc. | Linked target capture |
US11486004B2 (en) | 2020-07-13 | 2022-11-01 | Singular Genomics Systems, Inc. | Methods of sequencing circular template polynucleotides |
US11486001B2 (en) | 2021-02-08 | 2022-11-01 | Singular Genomics Systems, Inc. | Methods and compositions for sequencing complementary polynucleotides |
WO2022243480A1 (fr) | 2021-05-20 | 2022-11-24 | Illumina, Inc. | Compositions et procédés de séquençage par synthèse |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
WO2022256422A1 (fr) | 2021-06-02 | 2022-12-08 | 10X Genomics, Inc. | Analyse d'échantillon à l'aide de sondes circularisables asymétriques |
WO2022256324A1 (fr) | 2021-06-01 | 2022-12-08 | 10X Genomics, Inc. | Procédés et compositions pour la détection d'analytes et la résolution de sondes |
WO2022266125A1 (fr) * | 2021-06-15 | 2022-12-22 | Ultima Genomics, Inc. | Procédés de préparation de substrats de capture |
WO2023288225A1 (fr) | 2021-07-13 | 2023-01-19 | 10X Genomics, Inc. | Procédés de préparation d'une matrice polymérisée à épaisseur contrôlable |
WO2023015192A1 (fr) | 2021-08-03 | 2023-02-09 | 10X Genomics, Inc. | Concatémères d'acide nucléique et procédés de stabilisation et/ou de compactage de ceux-ci |
WO2023023484A1 (fr) | 2021-08-16 | 2023-02-23 | 10X Genomics, Inc. | Sondes comprenant une région de code-barres divisée et procédés d'utilisation |
US11608528B2 (en) | 2020-03-03 | 2023-03-21 | Pacific Biosciences Of California, Inc. | Methods and compositions for sequencing double stranded nucleic acids using RCA and MDA |
WO2023114896A1 (fr) | 2021-12-16 | 2023-06-22 | Illumina Cambridge Limited | Procédés de clivage dirigé par métal de polynucléotides liés à une surface |
WO2023122499A1 (fr) | 2021-12-20 | 2023-06-29 | Illumina Cambridge Limited | Compositions de périodate et procédés pour le clivage chimique de polynucléotides liés à la surface |
WO2023122491A1 (fr) | 2021-12-20 | 2023-06-29 | Illumina Cambridge Limited | Compositions de periodate et méthodes de clivage chimique de polynucléotides liés à la surface |
WO2023129898A2 (fr) | 2021-12-27 | 2023-07-06 | 10X Genomics, Inc. | Procédés et compositions pour l'amplification par cercle roulant |
WO2023141588A1 (fr) | 2022-01-21 | 2023-07-27 | 10X Genomics, Inc. | Signaux de lecture multiples pour analyser un échantillon |
WO2023164570A1 (fr) | 2022-02-23 | 2023-08-31 | Insitro, Inc. | Criblage optique groupé et mesures transcriptionnelles de cellules comprenant des perturbations génétiques à code-barres |
US11752483B2 (en) | 2012-05-21 | 2023-09-12 | The Scripps Research Institute | Methods of sample preparation |
WO2023186872A1 (fr) | 2022-03-30 | 2023-10-05 | Illumina Cambridge Limited | Procédés de clivage chimique de polynucléotides liés à une surface |
WO2023245190A1 (fr) | 2022-06-17 | 2023-12-21 | 10X Genomics, Inc. | DÉ-RÉTICULATION CATALYTIQUE D'ÉCHANTILLONS POUR ANALYSE IN SITU <i /> |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
WO2024036304A1 (fr) | 2022-08-12 | 2024-02-15 | 10X Genomics, Inc. | Polymérases puma1 et leurs utilisations |
WO2024040060A1 (fr) | 2022-08-16 | 2024-02-22 | 10X Genomics, Inc. | Ap50 polymérases et leurs utilisations |
WO2024039516A1 (fr) | 2022-08-19 | 2024-02-22 | Illumina, Inc. | Détection de la troisième paire de bases de l'adn spécifique de site |
WO2024081869A1 (fr) | 2022-10-14 | 2024-04-18 | 10X Genomics, Inc. | Procédés d'analyse d'échantillons biologiques |
WO2024102736A1 (fr) | 2022-11-08 | 2024-05-16 | 10X Genomics, Inc. | Procédés et compositions d'immobilisation pour détection in situ |
WO2024107887A1 (fr) | 2022-11-16 | 2024-05-23 | 10X Genomics, Inc. | Procédés et compositions pour évaluer les performances de dosages in situ |
Families Citing this family (245)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0514935D0 (en) | 2005-07-20 | 2005-08-24 | Solexa Ltd | Methods for sequencing a polynucleotide template |
GB0514910D0 (en) | 2005-07-20 | 2005-08-24 | Solexa Ltd | Method for sequencing a polynucleotide template |
GB0524069D0 (en) | 2005-11-25 | 2006-01-04 | Solexa Ltd | Preparation of templates for solid phase amplification |
DK1987159T4 (da) | 2006-02-08 | 2020-11-16 | Illumina Cambridge Ltd | Fremgangsmåde til sekventering af en polynukleotidtemplate |
US8241573B2 (en) | 2006-03-31 | 2012-08-14 | Illumina, Inc. | Systems and devices for sequence by synthesis analysis |
EP2032686B1 (fr) | 2006-06-23 | 2022-01-12 | Illumina, Inc. | Dispositif et méthode pour la création d'amas ordonnés d'adn |
US7754429B2 (en) | 2006-10-06 | 2010-07-13 | Illumina Cambridge Limited | Method for pair-wise sequencing a plurity of target polynucleotides |
US11940413B2 (en) | 2007-02-05 | 2024-03-26 | IsoPlexis Corporation | Methods and devices for sequencing nucleic acids in smaller batches |
EP2191011B1 (fr) * | 2007-08-29 | 2017-03-29 | Illumina Cambridge Limited | Procédé de séquençage d'une matrice de polynucléotides |
US8202691B2 (en) | 2008-01-25 | 2012-06-19 | Illumina, Inc. | Uniform fragmentation of DNA using binding proteins |
WO2009097368A2 (fr) | 2008-01-28 | 2009-08-06 | Complete Genomics, Inc. | Procédés et compositions pour un appel de base efficace dans des réactions de séquençage |
CN102124018A (zh) | 2008-04-29 | 2011-07-13 | 生命科技公司 | 可维持从核苷酸模板酶促合成双链核苷酸的非天然聚合酶底物及其使用的方法 |
US8039817B2 (en) | 2008-05-05 | 2011-10-18 | Illumina, Inc. | Compensator for multiple surface imaging |
WO2010038042A1 (fr) * | 2008-10-02 | 2010-04-08 | Illumina Cambridge Ltd. | Enrichissement d'échantillons d'acide nucléique pour des applications de séquençage |
WO2010062775A2 (fr) | 2008-11-03 | 2010-06-03 | The Regents Of The University Of California | Procédés de détection d'acides nucléiques résistant à une modification |
EP2607496B1 (fr) | 2008-12-23 | 2014-07-16 | Illumina, Inc. | Procédés utiles dans des protocoles de séquençage d'acide nucléique |
EP2425240A4 (fr) | 2009-04-30 | 2012-12-12 | Good Start Genetics Inc | Procédés et compositions d'évaluation de marqueurs génétiques |
SG10201407883PA (en) | 2009-12-07 | 2015-01-29 | Illumina Inc | Multi-sample indexing for multiplex genotyping |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
JP5893607B2 (ja) | 2010-04-05 | 2016-03-23 | プログノシス バイオサイエンシズ インコーポレイテッドPrognosys Biosciences,Inc. | 空間コード化生物学的アッセイ |
US8483969B2 (en) | 2010-09-17 | 2013-07-09 | Illuminia, Inc. | Variation analysis for multiple templates on a solid support |
US8759038B2 (en) | 2010-09-29 | 2014-06-24 | Illumina Cambridge Limited | Compositions and methods for sequencing nucleic acids |
EP2633069B1 (fr) | 2010-10-26 | 2015-07-01 | Illumina, Inc. | Procédés de séquençage |
EP3928867A1 (fr) | 2010-10-27 | 2021-12-29 | Illumina, Inc. | Microdispositifs et cartouches de biocapteur pour analyse chimique ou biologique et systèmes et procédés correspondants |
US8575071B2 (en) | 2010-11-03 | 2013-11-05 | Illumina, Inc. | Reducing adapter dimer formation |
AU2011323107B2 (en) | 2010-11-05 | 2015-09-10 | Illumina, Inc. | Linking sequence reads using paired code tags |
EP2643484A4 (fr) | 2010-11-22 | 2014-04-16 | Univ California | Procédés d'identification d'un transcrit cellulaire naissant d'arn |
US9163281B2 (en) | 2010-12-23 | 2015-10-20 | Good Start Genetics, Inc. | Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
US10152569B2 (en) | 2011-09-26 | 2018-12-11 | Gen-Probe Incorporated | Algorithms for sequence determinations |
US10378051B2 (en) | 2011-09-29 | 2019-08-13 | Illumina Cambridge Limited | Continuous extension and deblocking in reactions for nucleic acids synthesis and sequencing |
CA2852665A1 (fr) | 2011-10-17 | 2013-04-25 | Good Start Genetics, Inc. | Methodes d'identification de mutations associees a des maladies |
CA2854023A1 (fr) | 2011-11-07 | 2013-05-16 | Illumina, Inc. | Appareils de sequencage integre et procedes d'utilisation |
DK2788499T3 (en) | 2011-12-09 | 2016-03-21 | Illumina Inc | Enhanced root for polymer tags |
WO2013117595A2 (fr) | 2012-02-07 | 2013-08-15 | Illumina Cambridge Limited | Enrichissement et amplification ciblés d'acides nucléiques sur un support |
NO2694769T3 (fr) | 2012-03-06 | 2018-03-03 | ||
US8209130B1 (en) | 2012-04-04 | 2012-06-26 | Good Start Genetics, Inc. | Sequence assembly |
US8812422B2 (en) | 2012-04-09 | 2014-08-19 | Good Start Genetics, Inc. | Variant database |
US9444880B2 (en) | 2012-04-11 | 2016-09-13 | Illumina, Inc. | Cloud computing environment for biological data |
US10227635B2 (en) | 2012-04-16 | 2019-03-12 | Molecular Loop Biosolutions, Llc | Capture reactions |
WO2014008448A1 (fr) | 2012-07-03 | 2014-01-09 | Sloan Kettering Institute For Cancer Research | Évaluation quantitative de la reconstitution du répertoire des cellules t chez l'homme après une greffe allogénique de cellules souches hématopoïétiques |
ES2637538T3 (es) | 2012-07-17 | 2017-10-13 | Counsyl, Inc. | Sistema y métodos para la detección de una variación genética |
US9092401B2 (en) | 2012-10-31 | 2015-07-28 | Counsyl, Inc. | System and methods for detecting genetic variation |
NL2017959B1 (en) | 2016-12-08 | 2018-06-19 | Illumina Inc | Cartridge assembly |
US9116139B2 (en) | 2012-11-05 | 2015-08-25 | Illumina, Inc. | Sequence scheduling and sample distribution techniques |
US9805407B2 (en) | 2013-01-25 | 2017-10-31 | Illumina, Inc. | Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data |
EP3919617A1 (fr) | 2013-03-13 | 2021-12-08 | Illumina, Inc. | Procédés et compositions de séquençage d'acide nucléique |
WO2014152421A1 (fr) | 2013-03-14 | 2014-09-25 | Good Start Genetics, Inc. | Procédés d'analyse d'acides nucléiques |
US9255265B2 (en) | 2013-03-15 | 2016-02-09 | Illumina, Inc. | Methods for producing stranded cDNA libraries |
EP3005200A2 (fr) | 2013-06-03 | 2016-04-13 | Good Start Genetics, Inc. | Procédés et systèmes pour stocker des données de lecture de séquence |
EP3013983B1 (fr) | 2013-06-25 | 2023-02-15 | Prognosys Biosciences, Inc. | Essais biologiques à codage spatial faisant appel à un dispositif microfluidique |
WO2015015913A1 (fr) | 2013-07-31 | 2015-02-05 | 株式会社 日立ハイテクノロジーズ | Cuve à circulation pour analyse d'acides nucléiques et analyseur d'acides nucléiques |
US9352315B2 (en) | 2013-09-27 | 2016-05-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method to produce chemical pattern in micro-fluidic structure |
US11041203B2 (en) | 2013-10-18 | 2021-06-22 | Molecular Loop Biosolutions, Inc. | Methods for assessing a genomic region of a subject |
US10851414B2 (en) | 2013-10-18 | 2020-12-01 | Good Start Genetics, Inc. | Methods for determining carrier status |
US10540783B2 (en) | 2013-11-01 | 2020-01-21 | Illumina, Inc. | Image analysis useful for patterned objects |
LT3077943T (lt) | 2013-12-03 | 2020-10-12 | Illumina, Inc. | Vaizdo duomenų analizės būdai ir sistemos |
CN110411998B (zh) | 2013-12-10 | 2022-06-07 | 伊鲁米那股份有限公司 | 用于生物或化学分析的生物传感器及其制造方法 |
KR101982388B1 (ko) | 2014-02-13 | 2019-05-27 | 일루미나, 인코포레이티드 | 통합된 소비자 게놈 서비스 |
CN106164298B (zh) | 2014-02-18 | 2020-02-21 | 伊鲁米那股份有限公司 | 用于dna谱系分析的方法及组合物 |
CN110982689A (zh) | 2014-03-11 | 2020-04-10 | 伊鲁米那股份有限公司 | 一次性的集成微流体盒及其制备和使用的方法 |
US11053548B2 (en) | 2014-05-12 | 2021-07-06 | Good Start Genetics, Inc. | Methods for detecting aneuploidy |
DK3143161T3 (da) | 2014-05-16 | 2021-06-21 | Illumina Inc | Nukleinsyresynteseteknikker |
CA2949984C (fr) | 2014-05-27 | 2021-10-19 | Illumina, Inc. | Systemes et procedes d'analyse biochimique comprenant un instrument de base et une cartouche amovible |
LT3669985T (lt) | 2014-06-05 | 2022-06-10 | Illumina, Inc. | Sistemos, įskaitant sukamąjį vožtuvą, skirtos bent vieno mėginio paruošimui arba mėginio analizei |
US20150353989A1 (en) | 2014-06-09 | 2015-12-10 | Illumina Cambridge Limited | Sample preparation for nucleic acid amplification |
WO2016040446A1 (fr) | 2014-09-10 | 2016-03-17 | Good Start Genetics, Inc. | Procédés permettant la suppression sélective de séquences non cibles |
WO2016040602A1 (fr) | 2014-09-11 | 2016-03-17 | Epicentre Technologies Corporation | Séquence au bisulfite à représentation réduite utilisant de l'uracile n-glycosylase (ung) et de l'endonucléase iv |
JP2017536087A (ja) | 2014-09-24 | 2017-12-07 | グッド スタート ジェネティクス, インコーポレイテッド | 遺伝子アッセイのロバストネスを増大させるためのプロセス制御 |
CN106999850B (zh) | 2014-10-09 | 2020-04-07 | 亿明达股份有限公司 | 用于分离不混溶的液体以有效地隔离至少一种液体的方法和装置 |
US9897791B2 (en) | 2014-10-16 | 2018-02-20 | Illumina, Inc. | Optical scanning systems for in situ genetic analysis |
ES2768762T3 (es) | 2014-11-05 | 2020-06-23 | Illumina Cambridge Ltd | Reducción del daño al ADN durante la preparación de muestras y secuenciación usando agentes quelantes sideróforos |
GB201419731D0 (en) | 2014-11-05 | 2014-12-17 | Illumina Cambridge Ltd | Sequencing from multiple primers to increase data rate and density |
ES2802405T3 (es) | 2014-11-11 | 2021-01-19 | Illumina Cambridge Ltd | Métodos y matrices para producir y secuenciar agrupaciones monoclonales de ácido nucleico |
US10350570B2 (en) | 2014-12-15 | 2019-07-16 | Illumina, Inc. | Compositions and methods for single molecular placement on a substrate |
US9618474B2 (en) | 2014-12-18 | 2017-04-11 | Edico Genome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
US10006910B2 (en) | 2014-12-18 | 2018-06-26 | Agilome, Inc. | Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same |
US9857328B2 (en) | 2014-12-18 | 2018-01-02 | Agilome, Inc. | Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same |
CA2971589C (fr) | 2014-12-18 | 2021-09-28 | Edico Genome Corporation | Transistor a effet de champ chimiquement sensible |
US10020300B2 (en) | 2014-12-18 | 2018-07-10 | Agilome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
US9859394B2 (en) | 2014-12-18 | 2018-01-02 | Agilome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
EP4095261A1 (fr) | 2015-01-06 | 2022-11-30 | Molecular Loop Biosciences, Inc. | Criblage de variantes structurales |
KR20170135834A (ko) | 2015-02-10 | 2017-12-08 | 일루미나, 인코포레이티드 | 세포 성분을 분석하기 위한 방법 및 조성물 |
WO2016154038A1 (fr) | 2015-03-20 | 2016-09-29 | Illumina, Inc. | Cartouche fluidique pour une utilisation dans la position verticale ou sensiblement verticale |
EP3277839B1 (fr) | 2015-03-31 | 2020-12-02 | Illumina Cambridge Limited | Surface de concatémérisation de matrices |
CA2982146A1 (fr) | 2015-04-10 | 2016-10-13 | Spatial Transcriptomics Ab | Analyse de plusieurs acides nucleiques spatialement differencies de specimens biologiques |
US10844428B2 (en) | 2015-04-28 | 2020-11-24 | Illumina, Inc. | Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS) |
WO2016196358A1 (fr) | 2015-05-29 | 2016-12-08 | Epicentre Technologies Corporation | Méthodes d'analyse d'acides nucléiques |
DK3320111T3 (da) | 2015-07-06 | 2021-07-19 | Illumina Cambridge Ltd | Prøveklargøring til nukleinsyreamplifikation |
CA2993463A1 (fr) | 2015-07-27 | 2017-02-02 | Illumina, Inc. | Cartographie spatiale d'informations de sequence d'acide nucleique |
CN106435744B (zh) * | 2015-08-13 | 2022-02-01 | 生捷科技控股公司 | 使用y-接头和消失限制位点的文库构建 |
ES2868195T3 (es) | 2015-08-14 | 2021-10-21 | Illumina Inc | Sistemas y métodos que utilizan sensores magnéticamente sensibles para determinar una característica genética |
US10976334B2 (en) | 2015-08-24 | 2021-04-13 | Illumina, Inc. | In-line pressure accumulator and flow-control system for biological or chemical assays |
US10450598B2 (en) | 2015-09-11 | 2019-10-22 | Illumina, Inc. | Systems and methods for obtaining a droplet having a designated concentration of a substance-of-interest |
US10577643B2 (en) | 2015-10-07 | 2020-03-03 | Illumina, Inc. | Off-target capture reduction in sequencing techniques |
WO2017087724A1 (fr) | 2015-11-17 | 2017-05-26 | Omniome, Inc. | Procédés permettant de déterminer des profils de séquences |
WO2017201081A1 (fr) | 2016-05-16 | 2017-11-23 | Agilome, Inc. | Dispositifs à fet au graphène, systèmes et leurs méthodes d'utilisation pour le séquençage d'acides nucléiques |
KR102475710B1 (ko) | 2016-07-22 | 2022-12-08 | 오레곤 헬스 앤드 사이언스 유니버시티 | 단일 세포 전체 게놈 라이브러리 및 이의 제조를 위한 조합 인덱싱 방법 |
EP3510176A4 (fr) | 2016-09-12 | 2020-05-27 | Dana-Farber Cancer Institute, Inc. | Copolymérisation d'acrylamide pour la séquestration et la production d'acide nucléique simple brin |
NZ751798A (en) | 2016-09-22 | 2022-02-25 | Illumina Inc | Somatic copy number variation detection |
IL290157B2 (en) | 2016-10-14 | 2023-09-01 | Illumina Inc | cartridge kit |
CN110100009B (zh) | 2016-10-19 | 2023-11-21 | 伊鲁米那股份有限公司 | 核酸的化学连接方法 |
DK3566158T3 (da) | 2017-01-06 | 2022-07-18 | Illumina Inc | Faseinddelingskorrektion |
BR112019014042A2 (pt) | 2017-01-17 | 2020-02-04 | Illumina Inc | determinação de variante de splice oncogênica |
RU2022101605A (ru) | 2017-01-18 | 2022-03-25 | Иллюмина, Инк. | Способы и системы для получения наборов уникальных молекулярных индексов с гетерогенной длиной молекул и коррекции в них ошибок |
CA3050241C (fr) | 2017-01-20 | 2022-11-29 | Omniome, Inc. | Capture specifique d'un allele d'acides nucleiques |
EP3565900B1 (fr) | 2017-01-20 | 2021-04-07 | Omniome, Inc. | Génotypage par liaison par polymérase |
WO2018140329A1 (fr) | 2017-01-24 | 2018-08-02 | Tsavachidou Dimitra | Méthodes de construction de copies de molécules d'acide nucléique |
EP4053294A1 (fr) | 2017-03-24 | 2022-09-07 | Life Technologies Corporation | Adaptateurs polynucléotidiques et procédés d'utilisation de ces derniers |
CA3059952C (fr) | 2017-04-23 | 2023-04-18 | Illumina Cambridge Limited | Compositions et procedes pour ameliorer l'identification d'echantillons dans des bibliotheques d'acides nucleiques indexes |
SG11201909918XA (en) | 2017-04-23 | 2019-11-28 | Illumina Cambridge Ltd | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
EP3913053A1 (fr) | 2017-04-23 | 2021-11-24 | Illumina Cambridge Limited | Compositions et procédés permettant d'améliorer l'identification d'échantillons dans des bibliothèques d'acides nucléiques indexés |
SG11201909916YA (en) | 2017-04-23 | 2019-11-28 | Illumina Cambridge Ltd | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
WO2018204423A1 (fr) | 2017-05-01 | 2018-11-08 | Illumina, Inc. | Séquences index optimales pour séquençage multiplex massivement parallèle |
EP3622089A1 (fr) | 2017-05-08 | 2020-03-18 | Illumina, Inc. | Courts adaptateurs universels pour l'indexage d'échantillons de polynucléotides |
WO2018213803A1 (fr) | 2017-05-19 | 2018-11-22 | Neon Therapeutics, Inc. | Identification de néo-antigène immunogène |
ES2959047T3 (es) | 2017-06-07 | 2024-02-19 | Univ Oregon Health & Science | Bibliotecas de genoma completo de célula individual para la secuenciación de metilación |
WO2018236631A1 (fr) | 2017-06-20 | 2018-12-27 | Illumina, Inc. | Procédés et compositions pour résoudre les inefficacités dans des réactions d'amplification |
US20200202977A1 (en) | 2017-07-31 | 2020-06-25 | Illumina, Inc. | Sequencing system with multiplexed biological sample aggregation |
EP4289967A3 (fr) | 2017-08-01 | 2024-03-20 | Illumina, Inc. | Indexation spatiale de matériel génétique et préparation de pharmacothèque à l'aide de billes d'hydrogel et de cellules d'écoulement |
WO2019023924A1 (fr) | 2017-08-01 | 2019-02-07 | Helitec Limited | Procédés d'enrichissement et de détermination de séquences nucléotidiques cibles |
US11447818B2 (en) | 2017-09-15 | 2022-09-20 | Illumina, Inc. | Universal short adapters with variable length non-random unique molecular identifiers |
JP7091372B2 (ja) | 2017-11-06 | 2022-06-27 | イルミナ インコーポレイテッド | 核酸インデックス付け技術 |
CN110800061A (zh) | 2017-11-16 | 2020-02-14 | 伊鲁米那股份有限公司 | 用于确定微卫星不稳定性的系统和方法 |
AU2018375785A1 (en) | 2017-11-30 | 2019-12-12 | Illumina, Inc. | Validation methods and systems for sequence variant calls |
WO2019136376A1 (fr) | 2018-01-08 | 2019-07-11 | Illumina, Inc. | Séquençage à haut débit à détection à semi-conducteur |
KR102239487B1 (ko) | 2018-01-08 | 2021-04-14 | 일루미나, 인코포레이티드 | 반도체-기반 검출을 사용한 고-처리율 서열분석 |
WO2019195225A1 (fr) | 2018-04-02 | 2019-10-10 | Illumina, Inc. | Compositions et procédés de préparation de témoins pour un test génétique basé sur une séquence |
WO2019200026A1 (fr) * | 2018-04-12 | 2019-10-17 | Dana-Farber Cancer Institute, Inc. | Polymère sensible au méthanol à l'adn marqué pour la production d'acide nucléique monocaténaire |
SG11202001827UA (en) | 2018-05-17 | 2020-03-30 | Illumina Inc | High-throughput single-cell sequencing with reduced amplification bias |
EP3810774B1 (fr) | 2018-06-04 | 2023-09-13 | Illumina, Inc. | Procédés de production des bibliothèques de transcriptomes à une seule cellule à haut débit et leurs |
CN112955568A (zh) | 2018-08-15 | 2021-06-11 | Illumina公司 | 用于改善文库富集的组合物和方法 |
EP3844306A2 (fr) | 2018-08-28 | 2021-07-07 | 10X Genomics, Inc. | Augmentation de la résolution d'un réseau spatial |
EP3844308A1 (fr) | 2018-08-28 | 2021-07-07 | 10X Genomics, Inc. | Résolution de réseaux spatiaux |
US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
NL2022043B1 (en) | 2018-11-21 | 2020-06-03 | Akershus Univ Hf | Tagmentation-Associated Multiplex PCR Enrichment Sequencing |
CN112654718A (zh) | 2018-12-05 | 2021-04-13 | 伊卢米纳剑桥有限公司 | 通过桥式扩增进行簇生成的方法和组合物 |
EP3894587A1 (fr) | 2018-12-10 | 2021-10-20 | 10X Genomics, Inc. | Résolution de réseaux spatiaux par déconvolution basée sur la proximité |
SG11202012748TA (en) | 2018-12-14 | 2021-01-28 | Illumina Cambridge Ltd | Decreasing phasing with unlabeled nucleotides during sequencing |
EP3899036A1 (fr) | 2018-12-17 | 2021-10-27 | Illumina Cambridge Limited | Oligonucléotide d'amorce pour le séquençage |
CN112639125A (zh) | 2018-12-17 | 2021-04-09 | 伊卢米纳剑桥有限公司 | 用于多核苷酸测序的组合物 |
SG11202012807YA (en) | 2018-12-18 | 2021-01-28 | Illumina Cambridge Ltd | Methods and compositions for paired end sequencing using a single surface primer |
ES2965222T3 (es) | 2018-12-19 | 2024-04-11 | Illumina Inc | Métodos para mejorar la prioridad de clonalidad de agrupamientos de polinucleótidos |
US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
CN114174531A (zh) | 2019-02-28 | 2022-03-11 | 10X基因组学有限公司 | 用空间条码化寡核苷酸阵列对生物分析物进行概况分析 |
WO2020180778A1 (fr) | 2019-03-01 | 2020-09-10 | Illumina, Inc. | Banques de noyaux uniques et à cellule unique à haut rendement et leurs procédés de production et d'utilisation |
CN114127309A (zh) | 2019-03-15 | 2022-03-01 | 10X基因组学有限公司 | 使用空间阵列进行单细胞测序的方法 |
NL2023310B1 (en) | 2019-03-21 | 2020-09-28 | Illumina Inc | Training data generation for artificial intelligence-based sequencing |
NL2023311B9 (en) | 2019-03-21 | 2021-03-12 | Illumina Inc | Artificial intelligence-based generation of sequencing metadata |
US11210554B2 (en) | 2019-03-21 | 2021-12-28 | Illumina, Inc. | Artificial intelligence-based generation of sequencing metadata |
NL2023316B1 (en) | 2019-03-21 | 2020-09-28 | Illumina Inc | Artificial intelligence-based sequencing |
WO2020205296A1 (fr) | 2019-03-21 | 2020-10-08 | Illumina, Inc. | Génération à base d'intelligence artificielle de métadonnées de séquençage |
US11676685B2 (en) | 2019-03-21 | 2023-06-13 | Illumina, Inc. | Artificial intelligence-based quality scoring |
NL2023312B1 (en) | 2019-03-21 | 2020-09-28 | Illumina Inc | Artificial intelligence-based base calling |
EP3887542A1 (fr) | 2019-03-22 | 2021-10-06 | 10X Genomics, Inc. | Analyse spatiale tridimensionnelle |
US11423306B2 (en) | 2019-05-16 | 2022-08-23 | Illumina, Inc. | Systems and devices for characterization and performance analysis of pixel-based sequencing |
US11593649B2 (en) | 2019-05-16 | 2023-02-28 | Illumina, Inc. | Base calling using convolutions |
WO2020243579A1 (fr) | 2019-05-30 | 2020-12-03 | 10X Genomics, Inc. | Procédés de détection de l'hétérogénéité spatiale d'un échantillon biologique |
EP3798319A1 (fr) | 2019-09-30 | 2021-03-31 | Diagenode S.A. | Procédé de diagnostic et/ou de séquençage amélioré et kit |
EP3828283A1 (fr) | 2019-11-28 | 2021-06-02 | Diagenode S.A. | Procédé et kit de séquençage améliorés |
CN117036248A (zh) | 2019-10-01 | 2023-11-10 | 10X基因组学有限公司 | 用于识别组织样品中的形态学模式的系统和方法 |
WO2021091611A1 (fr) | 2019-11-08 | 2021-05-14 | 10X Genomics, Inc. | Agents de capture d'analytes marqués spatialement pour le multiplexage d'analytes |
WO2021102039A1 (fr) | 2019-11-21 | 2021-05-27 | 10X Genomics, Inc, | Analyse spatiale d'analytes |
US20220356461A1 (en) | 2019-12-19 | 2022-11-10 | Illumina, Inc. | High-throughput single-cell libraries and methods of making and of using |
KR20220143854A (ko) | 2020-02-20 | 2022-10-25 | 일루미나, 인코포레이티드 | 인공 지능 기반 다-대-다 염기 호출 |
US20210262018A1 (en) | 2020-02-21 | 2021-08-26 | 10X Genomics, Inc. | Methods and compositions for integrated in situ spatial assay |
DK3969618T3 (da) | 2020-03-09 | 2023-10-16 | Illumina Inc | Fremgangsmåder til sekventering af polynukleotider |
US11188778B1 (en) | 2020-05-05 | 2021-11-30 | Illumina, Inc. | Equalization-based image processing and spatial crosstalk attenuator |
JP2023524531A (ja) | 2020-05-08 | 2023-06-12 | イルミナ インコーポレイテッド | ゲノムシーケンシング及び検出手法 |
EP4150065A2 (fr) | 2020-05-12 | 2023-03-22 | Illumina Inc | Génération d'acides nucléiques avec des bases modifiées au moyen de désoxynucléotidyl transférase terminale recombinante |
WO2021252617A1 (fr) | 2020-06-09 | 2021-12-16 | Illumina, Inc. | Procédés pour augmenter le rendement de bibliothèques de séquençage |
CN115997033A (zh) | 2020-06-30 | 2023-04-21 | 伊鲁米纳公司 | 通过合成产生无痕dna的催化控制测序 |
WO2022010965A1 (fr) | 2020-07-08 | 2022-01-13 | Illumina, Inc. | Billes utilisées en tant que supports pour transposomes |
CN116157869A (zh) | 2020-12-02 | 2023-05-23 | 伊鲁米纳软件公司 | 用于检测遗传改变的系统和方法 |
US20220186300A1 (en) | 2020-12-11 | 2022-06-16 | 10X Genomics, Inc. | Methods and compositions for multimodal in situ analysis |
WO2022164809A1 (fr) | 2021-01-26 | 2022-08-04 | 10X Genomics, Inc. | Sondes analogiques d'acide nucléique pour analyse in situ |
CA3206511A1 (fr) | 2021-01-29 | 2022-08-04 | Yir-Shyuan WU | Procedes, compositions et kits pour ameliorer l'efficacite d'ensemencement de cellules d'ecoulement avec des polynucleotides |
WO2022197752A1 (fr) | 2021-03-16 | 2022-09-22 | Illumina, Inc. | Sélection d'ensembles de poids basée sur l'emplacement d'un élément et/ou le cycle pour appel de base |
CA3210451A1 (fr) | 2021-03-22 | 2022-09-29 | Illumina Cambridge Limited | Procedes d'amelioration de la clonalite de groupes d'acides nucleiques |
AU2022249734A1 (en) | 2021-03-31 | 2023-09-28 | Illumina Cambridge Limited | Nucleic acid library sequencing techniques with adapter dimer detection |
CN117043867A (zh) | 2021-04-02 | 2023-11-10 | 因美纳有限公司 | 用于检测用于测序的核苷酸样品玻片内的气泡的机器学习模型 |
US20220336054A1 (en) | 2021-04-15 | 2022-10-20 | Illumina, Inc. | Deep Convolutional Neural Networks to Predict Variant Pathogenicity using Three-Dimensional (3D) Protein Structures |
IL308031A (en) | 2021-04-29 | 2023-12-01 | Illumina Inc | Amplification techniques for nucleic acid characterization |
AU2022280886A1 (en) | 2021-05-28 | 2023-12-07 | Illumina, Inc. | Oligo-modified nucleotide analogues for nucleic acid preparation |
US20220403450A1 (en) | 2021-06-03 | 2022-12-22 | Illumina Software, Inc. | Systems and methods for sequencing nucleotides using two optical channels |
CN117597453A (zh) | 2021-06-23 | 2024-02-23 | 伊鲁米纳公司 | 用于测序试剂的组合物、方法、试剂盒、料筒和系统 |
IL309308A (en) | 2021-06-29 | 2024-02-01 | Illumina Inc | A signal-to-noise ratio measure for determining nucleotide base reads and base call quality |
KR20240026932A (ko) | 2021-06-29 | 2024-02-29 | 일루미나, 인코포레이티드 | 게놈 좌표에 대한 신뢰도 분류를 생성하기 위한 기계 학습 모델 |
WO2023278608A1 (fr) | 2021-06-29 | 2023-01-05 | Illumina, Inc. | Organe d'appel de base auto-appris, entraîné à l'aide d'oligo-séquences |
WO2023278184A1 (fr) | 2021-06-29 | 2023-01-05 | Illumina, Inc. | Procédés et systèmes pour corriger une diaphonie dans un éclairage émis par des sites de réaction |
US20230005253A1 (en) | 2021-07-01 | 2023-01-05 | Illumina, Inc. | Efficient artificial intelligence-based base calling of index sequences |
WO2023287617A1 (fr) | 2021-07-13 | 2023-01-19 | Illumina, Inc. | Procédés et systèmes pour l'extraction en temps réel de diaphonie dans un éclairage émis à partir de sites de réaction |
WO2023003757A1 (fr) | 2021-07-19 | 2023-01-26 | Illumina Software, Inc. | Extraction d'intensité avec interpolation et adaptation pour appel de base |
US11455487B1 (en) | 2021-10-26 | 2022-09-27 | Illumina Software, Inc. | Intensity extraction and crosstalk attenuation using interpolation and adaptation for base calling |
US20230021577A1 (en) | 2021-07-23 | 2023-01-26 | Illumina Software, Inc. | Machine-learning model for recalibrating nucleotide-base calls |
AU2022319125A1 (en) | 2021-07-28 | 2024-01-18 | Illumina, Inc. | Quality score calibration of basecalling systems |
WO2023014741A1 (fr) | 2021-08-03 | 2023-02-09 | Illumina Software, Inc. | Assignation de bases utilisant de multiples modèles de systèmes d'assignation de bases |
KR20240049214A (ko) | 2021-09-01 | 2024-04-16 | 일루미나, 인코포레이티드 | 가속 염기 호출을 위한 진폭 변조 |
CN117561573A (zh) | 2021-09-17 | 2024-02-13 | 因美纳有限公司 | 从碱基判读错误模式自动鉴定核苷酸测序中的故障来源 |
US20230095961A1 (en) | 2021-09-21 | 2023-03-30 | Illumina, Inc. | Graph reference genome and base-calling approach using imputed haplotypes |
US20230096386A1 (en) | 2021-09-30 | 2023-03-30 | Illumina Cambridge Limited | Polynucleotide sequencing |
WO2023102118A2 (fr) | 2021-12-01 | 2023-06-08 | 10X Genomics, Inc. | Procédés, compositions et systèmes pour la détection améliorée d'analytes in situ et analyse spatiale |
US20230343415A1 (en) | 2021-12-02 | 2023-10-26 | Illumina Software, Inc. | Generating cluster-specific-signal corrections for determining nucleotide-base calls |
WO2023107622A1 (fr) | 2021-12-10 | 2023-06-15 | Illumina, Inc. | Séquençage d'échantillons et d'indices parallèles |
WO2023114860A1 (fr) * | 2021-12-14 | 2023-06-22 | Arizona Board Of Regents On Behalf Of Arizona State University | Procédé de combinaison d'adn monocellulaire in situ et de séquençage d'arn |
AU2022409487A1 (en) | 2021-12-16 | 2024-01-18 | Illumina, Inc. | Hybrid clustering |
WO2023122363A1 (fr) | 2021-12-23 | 2023-06-29 | Illumina Software, Inc. | Résumés dynamiques d'état graphique pour séquençage de nucléotides |
US20230215515A1 (en) | 2021-12-23 | 2023-07-06 | Illumina Software, Inc. | Facilitating secure execution of external workflows for genomic sequencing diagnostics |
US20230207050A1 (en) | 2021-12-28 | 2023-06-29 | Illumina Software, Inc. | Machine learning model for recalibrating nucleotide base calls corresponding to target variants |
WO2023126457A1 (fr) | 2021-12-29 | 2023-07-06 | Illumina Cambridge Ltd. | Procédés de séquençage d'acide nucléique à l'aide d'amorces liées à une surface |
WO2023129764A1 (fr) | 2021-12-29 | 2023-07-06 | Illumina Software, Inc. | Permutation automatique des versions de modèle d'analyse de variants pour les applications d'analyse génomique |
WO2023164660A1 (fr) | 2022-02-25 | 2023-08-31 | Illumina, Inc. | Séquences d'étalonnage à des fins de séquençage de nucléotide |
US20230313271A1 (en) | 2022-02-25 | 2023-10-05 | Illumina, Inc. | Machine-learning models for detecting and adjusting values for nucleotide methylation levels |
AU2023233839A1 (en) | 2022-03-15 | 2024-01-18 | Illumina, Inc. | Concurrent sequencing of forward and reverse complement strands on concatenated polynucleotides for methylation detection |
EP4341435A1 (fr) | 2022-03-15 | 2024-03-27 | Illumina, Inc. | Procédés de reconnaissance de bases pour nucléobases |
US20230348973A1 (en) | 2022-03-31 | 2023-11-02 | Illumina Cambridge Limited | Paired-end re-synthesis using blocked p5 primers |
WO2023192616A1 (fr) | 2022-04-01 | 2023-10-05 | 10X Genomics, Inc. | Compositions et procédés de masquage ciblé d'autofluorescence |
US20230323427A1 (en) | 2022-04-06 | 2023-10-12 | 10X Genomics, Inc. | Methods and compositions for multiplex cell analysis |
WO2023196572A1 (fr) | 2022-04-07 | 2023-10-12 | Illumina Singapore Pte. Ltd. | Cytidine désaminases modifiées et méthodes d'utilisation |
CA3224264A1 (fr) | 2022-04-08 | 2023-10-12 | Illumina, Inc. | Techniques de detection et de compression de plage dynamique d'aptameres |
WO2023212601A1 (fr) | 2022-04-26 | 2023-11-02 | Illumina, Inc. | Modèles d'apprentissage automatique pour sélectionner des sondes oligonucléotidiques pour des technologies de réseau |
US20230348967A1 (en) | 2022-04-29 | 2023-11-02 | Illumina Cambridge Limited | Methods and systems for encapsulating lyophilised microspheres |
WO2023215612A1 (fr) | 2022-05-06 | 2023-11-09 | 10X Genomics, Inc. | Analyse d'un antigène et des interactions antigène-récepteur |
US20230368866A1 (en) | 2022-05-10 | 2023-11-16 | Illumina Software, Inc. | Adaptive neural network for nucelotide sequencing |
WO2023225095A1 (fr) | 2022-05-18 | 2023-11-23 | Illumina Cambridge Limited | Préparation de fragments d'acide nucléique à taille contrôlée |
US20230420080A1 (en) | 2022-06-24 | 2023-12-28 | Illumina Software, Inc. | Split-read alignment by intelligently identifying and scoring candidate split groups |
WO2024006779A1 (fr) | 2022-06-27 | 2024-01-04 | Illumina, Inc. | Accélérateurs pour un modèle d'imputation de génotypes |
WO2024006705A1 (fr) | 2022-06-27 | 2024-01-04 | Illumina Software, Inc. | Génotypage amélioré d'antigène leucocytaire humain (hla) |
WO2024006769A1 (fr) | 2022-06-27 | 2024-01-04 | Illumina Software, Inc. | Génération et mise en œuvre d'un génome à graphe de variation structurelle |
US20240038327A1 (en) | 2022-07-26 | 2024-02-01 | Illumina Software, Inc. | Rapid single-cell multiomics processing using an executable file |
WO2024059852A1 (fr) | 2022-09-16 | 2024-03-21 | Illumina, Inc. | Segmentation de grappes et appel de bases conditionnel |
US20240102067A1 (en) | 2022-09-26 | 2024-03-28 | Illumina, Inc. | Resynthesis Kits and Methods |
WO2024073516A1 (fr) | 2022-09-29 | 2024-04-04 | Illumina, Inc. | Panneau de référence de variant cible servant à imputer des variants cibles |
US20240110221A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Methods of modulating clustering kinetics |
US20240120027A1 (en) | 2022-09-30 | 2024-04-11 | Illumina, Inc. | Machine-learning model for refining structural variant calls |
US20240124914A1 (en) | 2022-09-30 | 2024-04-18 | Illumina, Inc. | Thermophilic compositions for nucleic acid amplification |
US20240124929A1 (en) | 2022-09-30 | 2024-04-18 | Illumina, Inc. | Mesophilic compositions for nucleic acid amplification |
WO2024069581A1 (fr) | 2022-09-30 | 2024-04-04 | Illumina Singapore Pte. Ltd. | Complexes hélicase-cytidine désaminase et procédés d'utilisation |
WO2024073047A1 (fr) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Cytidine désaminases et procédés d'utilisation dans la cartographie de nucléotides cytosine modifiés |
WO2024073043A1 (fr) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Procédés d'utilisation de protéines de liaison cpg dans la cartographie de nucléotides cytosine modifiés |
US20240110234A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Amplification Compositions and Methods |
US20240127905A1 (en) | 2022-10-05 | 2024-04-18 | Illumina, Inc. | Integrating variant calls from multiple sequencing pipelines utilizing a machine learning architecture |
US20240127906A1 (en) | 2022-10-11 | 2024-04-18 | Illumina, Inc. | Detecting and correcting methylation values from methylation sequencing assays |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300070B1 (en) * | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
US6372813B1 (en) * | 1999-06-25 | 2002-04-16 | Motorola | Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays |
US20020127575A1 (en) * | 2000-10-30 | 2002-09-12 | Glenn Hoke | Partially double-stranded nucleic acids, methods of making, and use thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112962A (en) * | 1989-04-19 | 1992-05-12 | Northwestern University | Labile anchors for solid phase polynucleotide synthesis |
US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
US5830655A (en) * | 1995-05-22 | 1998-11-03 | Sri International | Oligonucleotide sizing using cleavable primers |
US5747255A (en) † | 1995-09-29 | 1998-05-05 | Lynx Therapeutics, Inc. | Polynucleotide detection by isothermal amplification using cleavable oligonucleotides |
GB9620209D0 (en) * | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
EP1498494A3 (fr) | 1997-04-01 | 2007-06-20 | Solexa Ltd. | Procédé de séquencage d'acides nucléiques |
EP1591541B1 (fr) † | 1997-04-01 | 2012-02-15 | Illumina Cambridge Limited | Methode de séquençage d'acide nucléique |
AR021833A1 (es) † | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
US6391937B1 (en) † | 1998-11-25 | 2002-05-21 | Motorola, Inc. | Polyacrylamide hydrogels and hydrogel arrays made from polyacrylamide reactive prepolymers |
ATE296310T1 (de) † | 1999-03-08 | 2005-06-15 | Metrigen Inc | Syntheseverfahren zum ökonomischen aufbau langer dna-sequenzen und zusammensetzungen hierfür |
GB9907245D0 (en) † | 1999-03-29 | 1999-05-26 | Goldsborough Andrew | Cleavage of nucleic acids from solid supports |
US6664061B2 (en) | 1999-06-25 | 2003-12-16 | Amersham Biosciences Ab | Use and evaluation of a [2+2] photoaddition in immobilization of oligonucleotides on a three-dimensional hydrogel matrix |
WO2001062982A2 (fr) † | 2000-02-25 | 2001-08-30 | Mosaic Technologies, Inc. | Procedes destines a une amplification en phase solide en plusieurs etapes d'acides nucleiques |
WO2002012566A2 (fr) | 2000-08-09 | 2002-02-14 | Motorola, Inc. | Utilisation et evaluation d'une photocycloaddition [2+2] dans une immobilisation d'oligonucleotides sur une matrice hydrogel tridimensionnelle |
JPWO2003014394A1 (ja) | 2001-08-03 | 2004-11-25 | 旭メディカル株式会社 | 生体適合性評価法 |
WO2004011665A2 (fr) † | 2002-05-17 | 2004-02-05 | Nugen Technologies, Inc. | Procedes de fragmentation, d'etiquetage et d'immobilisation d'acides nucleiques |
WO2004016767A2 (fr) * | 2002-08-19 | 2004-02-26 | The President And Fellows Of Harvard College | Developpement d'une nouvelle fonction moleculaire |
DK1560838T3 (da) | 2002-08-23 | 2009-09-07 | Illumina Cambridge Ltd | M rkede nuklotider |
GB0324456D0 (en) | 2003-10-20 | 2003-11-19 | Isis Innovation | Parallel DNA sequencing methods |
EP2789383B1 (fr) * | 2004-01-07 | 2023-05-03 | Illumina Cambridge Limited | Réseaux moléculaires |
WO2006064199A1 (fr) * | 2004-12-13 | 2006-06-22 | Solexa Limited | Procede ameliore de detection de nucleotides |
GB0427236D0 (en) * | 2004-12-13 | 2005-01-12 | Solexa Ltd | Improved method of nucleotide detection |
GB0514936D0 (en) | 2005-07-20 | 2005-08-24 | Solexa Ltd | Preparation of templates for nucleic acid sequencing |
-
2005
- 2005-07-20 GB GBGB0514936.4A patent/GB0514936D0/en not_active Ceased
-
2006
- 2006-07-20 ES ES10011728T patent/ES2398808T5/es active Active
- 2006-07-20 US US11/989,169 patent/US20090118128A1/en not_active Abandoned
- 2006-07-20 WO PCT/GB2006/002687 patent/WO2007010251A2/fr active Application Filing
- 2006-07-20 EP EP06755781A patent/EP1910559B1/fr active Active
- 2006-07-20 EP EP10011728.2A patent/EP2298930B2/fr active Active
-
2011
- 2011-08-23 HK HK11108861.6A patent/HK1154636A1/xx unknown
-
2012
- 2012-04-19 US US13/450,920 patent/US8715966B2/en active Active
-
2014
- 2014-01-28 US US14/166,670 patent/US9085802B2/en active Active
-
2015
- 2015-06-12 US US14/738,591 patent/US9498763B2/en active Active
-
2016
- 2016-10-06 US US15/287,077 patent/US9999866B2/en active Active
-
2018
- 2018-06-18 US US16/010,902 patent/US10710046B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300070B1 (en) * | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
US6372813B1 (en) * | 1999-06-25 | 2002-04-16 | Motorola | Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays |
US20020127575A1 (en) * | 2000-10-30 | 2002-09-12 | Glenn Hoke | Partially double-stranded nucleic acids, methods of making, and use thereof |
Cited By (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11187702B2 (en) | 2003-03-14 | 2021-11-30 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US9857303B2 (en) | 2003-03-31 | 2018-01-02 | Medical Research Council | Selection by compartmentalised screening |
US10052605B2 (en) | 2003-03-31 | 2018-08-21 | Medical Research Council | Method of synthesis and testing of combinatorial libraries using microcapsules |
US9448172B2 (en) | 2003-03-31 | 2016-09-20 | Medical Research Council | Selection by compartmentalised screening |
US11821109B2 (en) | 2004-03-31 | 2023-11-21 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
US9925504B2 (en) | 2004-03-31 | 2018-03-27 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
US9839890B2 (en) | 2004-03-31 | 2017-12-12 | National Science Foundation | Compartmentalised combinatorial chemistry by microfluidic control |
US8871444B2 (en) | 2004-10-08 | 2014-10-28 | Medical Research Council | In vitro evolution in microfluidic systems |
US11786872B2 (en) | 2004-10-08 | 2023-10-17 | United Kingdom Research And Innovation | Vitro evolution in microfluidic systems |
US9029083B2 (en) | 2004-10-08 | 2015-05-12 | Medical Research Council | Vitro evolution in microfluidic systems |
US9186643B2 (en) | 2004-10-08 | 2015-11-17 | Medical Research Council | In vitro evolution in microfluidic systems |
US9498759B2 (en) | 2004-10-12 | 2016-11-22 | President And Fellows Of Harvard College | Compartmentalized screening by microfluidic control |
US9999866B2 (en) | 2005-07-20 | 2018-06-19 | Illumina Cambridge Limited | Preparation of templates for nucleic acid sequencing |
US10710046B2 (en) | 2005-07-20 | 2020-07-14 | Illumina Cambridge Limited | Preparation of templates for nucleic acid sequencing |
US9534216B2 (en) | 2006-01-11 | 2017-01-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9410151B2 (en) | 2006-01-11 | 2016-08-09 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US9328344B2 (en) | 2006-01-11 | 2016-05-03 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
US11351510B2 (en) | 2006-05-11 | 2022-06-07 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US9273308B2 (en) | 2006-05-11 | 2016-03-01 | Raindance Technologies, Inc. | Selection of compartmentalized screening method |
US9498761B2 (en) | 2006-08-07 | 2016-11-22 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US10603662B2 (en) | 2007-02-06 | 2020-03-31 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US11819849B2 (en) | 2007-02-06 | 2023-11-21 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US9440232B2 (en) | 2007-02-06 | 2016-09-13 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US9017623B2 (en) | 2007-02-06 | 2015-04-28 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US10960397B2 (en) | 2007-04-19 | 2021-03-30 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10675626B2 (en) | 2007-04-19 | 2020-06-09 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11224876B2 (en) | 2007-04-19 | 2022-01-18 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11618024B2 (en) | 2007-04-19 | 2023-04-04 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10357772B2 (en) | 2007-04-19 | 2019-07-23 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US9068699B2 (en) | 2007-04-19 | 2015-06-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US8741571B2 (en) | 2008-07-02 | 2014-06-03 | Illumina Cambridge Limited | Using populations of beads for the fabrication of arrays on surfaces |
US9677069B2 (en) | 2008-07-02 | 2017-06-13 | Illumina Cambridge Limited | Nucleic acid arrays of spatially discrete features on a surface |
US8198028B2 (en) | 2008-07-02 | 2012-06-12 | Illumina Cambridge Limited | Using populations of beads for the fabrication of arrays on surfaces |
US8399192B2 (en) | 2008-07-02 | 2013-03-19 | Illumina Cambridge Limited | Using populations of beads for the fabrication of arrays on surfaces |
US9079148B2 (en) | 2008-07-02 | 2015-07-14 | Illumina Cambridge Limited | Using populations of beads for the fabrication of arrays on surfaces |
US10287577B2 (en) | 2008-07-02 | 2019-05-14 | Illumina Cambridge Ltd. | Nucleic acid arrays of spatially discrete features on a surface |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US11596908B2 (en) | 2008-07-18 | 2023-03-07 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11534727B2 (en) | 2008-07-18 | 2022-12-27 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US8528589B2 (en) | 2009-03-23 | 2013-09-10 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
US11268887B2 (en) | 2009-03-23 | 2022-03-08 | Bio-Rad Laboratories, Inc. | Manipulation of microfluidic droplets |
US10036063B2 (en) | 2009-07-24 | 2018-07-31 | Illumina, Inc. | Method for sequencing a polynucleotide template |
EP3133169A1 (fr) | 2009-08-25 | 2017-02-22 | Illumina, Inc. | Procédés de sélection et d'amplification de polynucléotides |
EP2669387A1 (fr) | 2009-08-25 | 2013-12-04 | Illumina, Inc. | Procédés de sélection et d'amplification de polynucléotides |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US9074242B2 (en) | 2010-02-12 | 2015-07-07 | Raindance Technologies, Inc. | Digital analyte analysis |
US8535889B2 (en) | 2010-02-12 | 2013-09-17 | Raindance Technologies, Inc. | Digital analyte analysis |
US11254968B2 (en) | 2010-02-12 | 2022-02-22 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10808279B2 (en) | 2010-02-12 | 2020-10-20 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US11390917B2 (en) | 2010-02-12 | 2022-07-19 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9228229B2 (en) | 2010-02-12 | 2016-01-05 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9469872B2 (en) | 2010-02-23 | 2016-10-18 | Illumina Cambridge Limited | Amplification methods to minimise sequence specific bias |
US8759037B2 (en) | 2010-02-23 | 2014-06-24 | Illumina Cambridge Limited | Amplification methods to minimise sequence specific bias |
US10428363B2 (en) | 2010-02-23 | 2019-10-01 | Illumina Cambridge Limited | Amplification methods to minimise sequence specific bias |
US11279975B2 (en) | 2010-08-27 | 2022-03-22 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
US10329613B2 (en) | 2010-08-27 | 2019-06-25 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
WO2012025250A1 (fr) | 2010-08-27 | 2012-03-01 | Illumina Cambridge Ltd. | Méthodes de séquençage de polynucléotides |
EP3205730A1 (fr) | 2010-08-27 | 2017-08-16 | Illumina Cambridge Limited | Méthodes de séquencage en «paired end» de polynucléotides |
EP2801623A1 (fr) | 2010-08-27 | 2014-11-12 | Illumina Cambridge Limited | Méthodes de séquencage de polynucléotides |
US9029103B2 (en) | 2010-08-27 | 2015-05-12 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
US11635427B2 (en) | 2010-09-30 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
US11077415B2 (en) | 2011-02-11 | 2021-08-03 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
US11168353B2 (en) | 2011-02-18 | 2021-11-09 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11965877B2 (en) | 2011-02-18 | 2024-04-23 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11768198B2 (en) | 2011-02-18 | 2023-09-26 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
EP3736281A1 (fr) | 2011-02-18 | 2020-11-11 | Bio-Rad Laboratories, Inc. | Compositions et méthodes de marquage moléculaire |
US11747327B2 (en) | 2011-02-18 | 2023-09-05 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US11754499B2 (en) | 2011-06-02 | 2023-09-12 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US11898193B2 (en) | 2011-07-20 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Manipulating droplet size |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
EP3309262A1 (fr) | 2012-02-24 | 2018-04-18 | Raindance Technologies, Inc. | Marquage et préparation d'échantillon pour le séquençage |
WO2013126741A1 (fr) | 2012-02-24 | 2013-08-29 | Raindance Technologies, Inc. | Marquage et préparation d'échantillon pour le séquençage |
US11752483B2 (en) | 2012-05-21 | 2023-09-12 | The Scripps Research Institute | Methods of sample preparation |
US10975210B2 (en) * | 2013-07-01 | 2021-04-13 | Illumina, Inc. | Catalyst-free surface functionalization and polymer grafting |
US11618808B2 (en) | 2013-07-01 | 2023-04-04 | Illumina, Inc. | Catalyst-free surface functionalization and polymer grafting |
US20180265660A1 (en) * | 2013-07-01 | 2018-09-20 | Illumina, Inc. | Catalyst-free surface functionalization and polymer grafting |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US11174509B2 (en) | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
US10537889B2 (en) | 2013-12-31 | 2020-01-21 | Illumina, Inc. | Addressable flow cell using patterned electrodes |
WO2015108663A1 (fr) | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Préparation et séquençage d'amplicons sur supports solides |
US10865444B2 (en) | 2014-01-16 | 2020-12-15 | Illumina, Inc. | Amplicon preparation and sequencing on solid supports |
US11214798B2 (en) * | 2014-09-09 | 2022-01-04 | Igenomx International Genomics Corporation | Methods and compositions for rapid nucleic acid library preparation |
US10000799B2 (en) | 2014-11-04 | 2018-06-19 | Boreal Genomics, Inc. | Methods of sequencing with linked fragments |
US10829813B2 (en) | 2014-11-04 | 2020-11-10 | Boreal Genomics, Inc. | Methods of sequencing with linked fragments |
US11827930B2 (en) | 2014-11-04 | 2023-11-28 | Ncan Genomics, Inc. | Methods of sequencing with linked fragments |
CN107849598A (zh) * | 2015-05-29 | 2018-03-27 | 伊卢米纳剑桥有限公司 | 簇中的表面引物的增强利用 |
US20180142281A1 (en) * | 2015-05-29 | 2018-05-24 | Illumina Cambridge Limited | Enhanced utilization of surface primers in clusters |
US10590464B2 (en) * | 2015-05-29 | 2020-03-17 | Illumina Cambridge Limited | Enhanced utilization of surface primers in clusters |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
WO2017168332A1 (fr) | 2016-03-28 | 2017-10-05 | Boreal Genomics, Inc. | Capture de cible duplex liée |
US10801059B2 (en) | 2016-03-28 | 2020-10-13 | Boreal Genomics, Inc. | Droplet-based linked-fragment sequencing |
EP4282974A2 (fr) | 2016-03-28 | 2023-11-29 | Ncan Genomics, Inc. | Capture de cible duplex liée |
US11905556B2 (en) | 2016-03-28 | 2024-02-20 | Ncan Genomics, Inc. | Linked target capture |
US10961573B2 (en) | 2016-03-28 | 2021-03-30 | Boreal Genomics, Inc. | Linked duplex target capture |
US10961568B2 (en) | 2016-03-28 | 2021-03-30 | Boreal Genomics, Inc. | Linked target capture |
US11021742B2 (en) | 2016-03-28 | 2021-06-01 | Boreal Genomics, Inc. | Linked-fragment sequencing |
US11879151B2 (en) | 2016-12-09 | 2024-01-23 | Ncan Genomics, Inc. | Linked ligation |
US11268137B2 (en) | 2016-12-09 | 2022-03-08 | Boreal Genomics, Inc. | Linked ligation |
JP2020503022A (ja) * | 2016-12-22 | 2020-01-30 | イラミーナ インコーポレーテッド | 配列決定プライマーおよび非配列決定エンティティを含むアレイ |
WO2018119057A2 (fr) | 2016-12-22 | 2018-06-28 | Illumina, Inc. | Réseau comprenant une amorce de séquençage et une entité non de séquençage |
AU2017379867B2 (en) * | 2016-12-22 | 2022-10-20 | Illumina, Inc. | Array including sequencing primer and non-sequencing entity |
JP7051869B2 (ja) | 2016-12-22 | 2022-04-11 | イラミーナ インコーポレーテッド | 配列決定プライマーおよび非配列決定エンティティを含むアレイ |
IL267445B1 (en) * | 2016-12-22 | 2023-06-01 | Illumina Inc | An array that includes a genetic tiling primer and a non tiling entity |
KR20190094391A (ko) * | 2016-12-22 | 2019-08-13 | 일루미나, 인코포레이티드 | 시퀀싱 프라이머 및 비-시퀀싱 존재물을 포함하는 어레이 |
EP3558510A4 (fr) * | 2016-12-22 | 2020-08-19 | Illumina, Inc. | Réseau comprenant une amorce de séquençage et une entité non de séquençage |
US11466321B2 (en) * | 2016-12-22 | 2022-10-11 | Illumina, Inc. | Array including sequencing primer and non-sequencing entity |
KR102586847B1 (ko) | 2016-12-22 | 2023-10-10 | 일루미나, 인코포레이티드 | 시퀀싱 프라이머 및 비-시퀀싱 존재물을 포함하는 어레이 |
EP4306532A2 (fr) | 2018-05-15 | 2024-01-17 | Illumina, Inc. | Clivage et deprotection chimiques |
WO2019222264A1 (fr) | 2018-05-15 | 2019-11-21 | Illumina, Inc. | Compositions, procédés de clivage chimique et procédés de déprotection d'oligonucléotides liés à une surface |
US11827931B2 (en) | 2018-12-26 | 2023-11-28 | Illumina Cambridge Limited | Methods of preparing growing polynucleotides using nucleotides with 3′ AOM blocking group |
WO2020136170A2 (fr) | 2018-12-26 | 2020-07-02 | Illumina Cambridge Limited | Nucléosides et nucléotides avec des groupes de blocage 3'-hydroxy |
US11293061B2 (en) | 2018-12-26 | 2022-04-05 | Illumina Cambridge Limited | Sequencing methods using nucleotides with 3′ AOM blocking group |
US11473136B2 (en) | 2019-01-03 | 2022-10-18 | Ncan Genomics, Inc. | Linked target capture |
WO2021167986A1 (fr) | 2020-02-17 | 2021-08-26 | 10X Genomics, Inc. | Analyse in situ de l'interaction chromatinienne |
US11608528B2 (en) | 2020-03-03 | 2023-03-21 | Pacific Biosciences Of California, Inc. | Methods and compositions for sequencing double stranded nucleic acids using RCA and MDA |
US11891660B2 (en) | 2020-03-06 | 2024-02-06 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
US11365445B2 (en) | 2020-03-06 | 2022-06-21 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
US11359238B2 (en) | 2020-03-06 | 2022-06-14 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
US11519029B2 (en) | 2020-03-06 | 2022-12-06 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
US11787831B2 (en) | 2020-06-22 | 2023-10-17 | Illumina Cambridge Limited | Nucleosides and nucleotides with 3′ acetal blocking group |
WO2021259881A1 (fr) | 2020-06-22 | 2021-12-30 | Illumina Cambridge Limited | Nucléosides et nucléotides avec groupe de blocage acétal 3' |
US11486004B2 (en) | 2020-07-13 | 2022-11-01 | Singular Genomics Systems, Inc. | Methods of sequencing circular template polynucleotides |
WO2022159474A1 (fr) | 2021-01-19 | 2022-07-28 | 10X Genomics, Inc. | Procédés et compositions pour dosages in situ par étalon interne |
US11560590B2 (en) | 2021-02-08 | 2023-01-24 | Singular Genomics Systems, Inc. | Methods and compositions for sequencing complementary polynucleotides |
US11913071B2 (en) | 2021-02-08 | 2024-02-27 | Singular Genomics Systems, Inc. | Methods and compositions for sequencing complementary polynucleotides |
US11788133B2 (en) | 2021-02-08 | 2023-10-17 | Singular Genomics Systems, Inc. | Methods and compositions for sequencing complementary polynucleotides |
US11486001B2 (en) | 2021-02-08 | 2022-11-01 | Singular Genomics Systems, Inc. | Methods and compositions for sequencing complementary polynucleotides |
WO2022187366A1 (fr) | 2021-03-03 | 2022-09-09 | 10X Genomics, Inc. | Détection d'analytes in situ à l'aide d'origami d'acide nucléique |
WO2022243480A1 (fr) | 2021-05-20 | 2022-11-24 | Illumina, Inc. | Compositions et procédés de séquençage par synthèse |
WO2022256324A1 (fr) | 2021-06-01 | 2022-12-08 | 10X Genomics, Inc. | Procédés et compositions pour la détection d'analytes et la résolution de sondes |
WO2022256422A1 (fr) | 2021-06-02 | 2022-12-08 | 10X Genomics, Inc. | Analyse d'échantillon à l'aide de sondes circularisables asymétriques |
WO2022266125A1 (fr) * | 2021-06-15 | 2022-12-22 | Ultima Genomics, Inc. | Procédés de préparation de substrats de capture |
WO2023288225A1 (fr) | 2021-07-13 | 2023-01-19 | 10X Genomics, Inc. | Procédés de préparation d'une matrice polymérisée à épaisseur contrôlable |
WO2023015192A1 (fr) | 2021-08-03 | 2023-02-09 | 10X Genomics, Inc. | Concatémères d'acide nucléique et procédés de stabilisation et/ou de compactage de ceux-ci |
WO2023023484A1 (fr) | 2021-08-16 | 2023-02-23 | 10X Genomics, Inc. | Sondes comprenant une région de code-barres divisée et procédés d'utilisation |
WO2023114896A1 (fr) | 2021-12-16 | 2023-06-22 | Illumina Cambridge Limited | Procédés de clivage dirigé par métal de polynucléotides liés à une surface |
WO2023122491A1 (fr) | 2021-12-20 | 2023-06-29 | Illumina Cambridge Limited | Compositions de periodate et méthodes de clivage chimique de polynucléotides liés à la surface |
WO2023122499A1 (fr) | 2021-12-20 | 2023-06-29 | Illumina Cambridge Limited | Compositions de périodate et procédés pour le clivage chimique de polynucléotides liés à la surface |
WO2023129898A2 (fr) | 2021-12-27 | 2023-07-06 | 10X Genomics, Inc. | Procédés et compositions pour l'amplification par cercle roulant |
WO2023141588A1 (fr) | 2022-01-21 | 2023-07-27 | 10X Genomics, Inc. | Signaux de lecture multiples pour analyser un échantillon |
CN114457146A (zh) * | 2022-01-28 | 2022-05-10 | 赛纳生物科技(北京)有限公司 | 一种固相介质表面双端扩增测序的方法 |
WO2023164570A1 (fr) | 2022-02-23 | 2023-08-31 | Insitro, Inc. | Criblage optique groupé et mesures transcriptionnelles de cellules comprenant des perturbations génétiques à code-barres |
WO2023186872A1 (fr) | 2022-03-30 | 2023-10-05 | Illumina Cambridge Limited | Procédés de clivage chimique de polynucléotides liés à une surface |
WO2023245190A1 (fr) | 2022-06-17 | 2023-12-21 | 10X Genomics, Inc. | DÉ-RÉTICULATION CATALYTIQUE D'ÉCHANTILLONS POUR ANALYSE IN SITU <i /> |
WO2024036304A1 (fr) | 2022-08-12 | 2024-02-15 | 10X Genomics, Inc. | Polymérases puma1 et leurs utilisations |
WO2024040060A1 (fr) | 2022-08-16 | 2024-02-22 | 10X Genomics, Inc. | Ap50 polymérases et leurs utilisations |
WO2024039516A1 (fr) | 2022-08-19 | 2024-02-22 | Illumina, Inc. | Détection de la troisième paire de bases de l'adn spécifique de site |
WO2024081869A1 (fr) | 2022-10-14 | 2024-04-18 | 10X Genomics, Inc. | Procédés d'analyse d'échantillons biologiques |
WO2024102736A1 (fr) | 2022-11-08 | 2024-05-16 | 10X Genomics, Inc. | Procédés et compositions d'immobilisation pour détection in situ |
WO2024107887A1 (fr) | 2022-11-16 | 2024-05-23 | 10X Genomics, Inc. | Procédés et compositions pour évaluer les performances de dosages in situ |
Also Published As
Publication number | Publication date |
---|---|
GB0514936D0 (en) | 2005-08-24 |
US8715966B2 (en) | 2014-05-06 |
US10710046B2 (en) | 2020-07-14 |
ES2398808T3 (es) | 2013-03-21 |
US9999866B2 (en) | 2018-06-19 |
EP1910559A2 (fr) | 2008-04-16 |
US20120208194A1 (en) | 2012-08-16 |
US9085802B2 (en) | 2015-07-21 |
US20150343410A1 (en) | 2015-12-03 |
EP1910559B1 (fr) | 2012-06-13 |
HK1154636A1 (en) | 2012-04-27 |
EP2298930A1 (fr) | 2011-03-23 |
ES2398808T5 (es) | 2022-11-04 |
WO2007010251A3 (fr) | 2007-08-30 |
WO2007010251A2 (fr) | 2007-01-25 |
US20140349891A1 (en) | 2014-11-27 |
US20180353926A1 (en) | 2018-12-13 |
EP2298930B2 (fr) | 2022-06-29 |
US9498763B2 (en) | 2016-11-22 |
US20170021325A1 (en) | 2017-01-26 |
EP2298930B1 (fr) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10710046B2 (en) | Preparation of templates for nucleic acid sequencing | |
US10221452B2 (en) | Method for pairwise sequencing of target polynucleotides | |
US10876158B2 (en) | Method for sequencing a polynucleotide template | |
US20090117621A1 (en) | Methods of nucleic acid amplification and sequencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SOLEXA LIMITED, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, XIAOHAI;MILTON, JOHN;SMITH, GEOFFREY PAUL;AND OTHERS;REEL/FRAME:022986/0851;SIGNING DATES FROM 20080211 TO 20080218 |
|
AS | Assignment |
Owner name: ILLUMINA CAMBRIDGE LIMITED, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:SOLEXA LIMITED;REEL/FRAME:025759/0114 Effective date: 20080104 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |